LIHUI的个人主页 - 老虎社区

LIHUI

LIHUI

暂无个人介绍

IP属地：未知

55关注

4粉丝

0主题

0勋章

2021-07-12

.

Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote>

2021-07-12

.

抱歉，原内容已删除

2021-06-08

Like please

Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健(Biogen)阿尔茨海默病药物获得FDA批准</blockquote>

2021-06-04

.

抱歉，原内容已删除

2021-06-03

.

抱歉，原内容已删除

2021-06-02

.

AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC股价再次飙升。如何理解这一举动。</blockquote>

2021-06-01

.

抱歉，原内容已删除

2021-06-01

Weeee

Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将报告第一季度收益：前景如何？</blockquote>

2021-05-28

.

抱歉，原内容已删除

2021-05-27

.guu ya n

2021-05-27

.

抱歉，原内容已删除

2021-05-26

.

抱歉，原内容已删除

2021-05-20

.

抱歉，原内容已删除

2021-05-18

.

抱歉，原内容已删除

2021-05-16

.

Why AMC Entertainment Stock Jumped Again Friday<blockquote>为什么AMC院线股价周五再次上涨</blockquote>

2021-05-14

Thanks for sharing

Opinion: Why any stock market rally right now will be quick<blockquote>观点：为什么现在股市反弹会很快</blockquote>

2021-05-12

$Starbucks(SBUX)$dhisndf

2021-05-12

Uppppzz

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3579418112520180","uuid":"3579418112520180","gmtCreate":1616324571094,"gmtModify":1620830636840,"name":"LIHUI","pinyin":"lihui","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":55,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.66%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":142067113,"gmtCreate":1626104891732,"gmtModify":1631889244205,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142067113","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","kind":"news","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=zh_CN&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p><p><blockquote>（彭博社）-油价小幅走低，交易商正在努力应对几个地区新冠肺炎疫情死灰复燃和中国经济增长放缓对需求的影响。</blockquote></p><p> Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p><p><blockquote>纽约期货周一跌幅高达1.9%。日、韩、越部分地区为遏制德尔塔变异毒株疫情蔓延出台了新的流动限制措施，令石油需求前景蒙上阴影。与此同时，据报道，中国经济反弹放缓。美元走强也打压了价格，降低了以美元计价的大宗商品的吸引力。</blockquote></p><p> “As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p><p><blockquote>Again Capital LLC合伙人约翰·基尔达夫(John Kilduff)表示：“随着Covid-19变种继续严重打击亚洲，而亚洲确实是关键的摇摆需求中心，这对该综合体来说是一个非常非常大的负面影响。”</blockquote></p><p> Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p><p><blockquote>在全球供应紧张的情况下，美国和中国等经济体的燃料消耗今年提振了油价。OPEC及其盟友未能就增加供应达成一致，造成市场波动，并推动原油上周出现自5月以来的首次单周下跌。中国经济复苏放缓和德尔塔变异毒株蔓延可能威胁到全球石油需求和大宗商品今年迄今的走势。</blockquote></p><p> China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p><p><blockquote>根据彭博对经济学家的调查，中国第二季度的增长从第一季度创纪录的18.3%放缓至8%。零售销售和工业生产预计也将放缓。</blockquote></p><p> “There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p><p><blockquote>荷兰银行高级能源经济学家Hans van Cleef表示：“中国数据疲软，但欧洲德尔塔变异毒株的上升也引发了人们对需求复苏的一些怀疑。”</blockquote></p><p> The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p><p><blockquote>德尔塔变异毒株已经蔓延到世界各地，包括自5月中旬以来报告病例最多的美国。在欧洲，英国和法国官员正在就新病例和重新开放发出警告。</blockquote></p><p> Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p><p><blockquote>欧佩克+即将供应的不确定性继续笼罩着市场。在成员国之间就减产发生争执后，该联盟上周放弃了会议，一周后，仍未达成协议。</blockquote></p><p> “They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p><p><blockquote>Again Capital LLC的基尔达夫表示：“他们将在一定程度上提高，这只是幅度以及是否会崩溃的问题。”</blockquote></p><p> The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p><p><blockquote>国际能源署将于周二发布月度报告，为投资者提供市场概况，而OPEC将于周四发布自己的月度报告。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-07-12 23:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p><p><blockquote>（彭博社）-油价小幅走低，交易商正在努力应对几个地区新冠肺炎疫情死灰复燃和中国经济增长放缓对需求的影响。</blockquote></p><p> Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p><p><blockquote>纽约期货周一跌幅高达1.9%。日、韩、越部分地区为遏制德尔塔变异毒株疫情蔓延出台了新的流动限制措施，令石油需求前景蒙上阴影。与此同时，据报道，中国经济反弹放缓。美元走强也打压了价格，降低了以美元计价的大宗商品的吸引力。</blockquote></p><p> “As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p><p><blockquote>Again Capital LLC合伙人约翰·基尔达夫(John Kilduff)表示：“随着Covid-19变种继续严重打击亚洲，而亚洲确实是关键的摇摆需求中心，这对该综合体来说是一个非常非常大的负面影响。”</blockquote></p><p> Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p><p><blockquote>在全球供应紧张的情况下，美国和中国等经济体的燃料消耗今年提振了油价。OPEC及其盟友未能就增加供应达成一致，造成市场波动，并推动原油上周出现自5月以来的首次单周下跌。中国经济复苏放缓和德尔塔变异毒株蔓延可能威胁到全球石油需求和大宗商品今年迄今的走势。</blockquote></p><p> China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p><p><blockquote>根据彭博对经济学家的调查，中国第二季度的增长从第一季度创纪录的18.3%放缓至8%。零售销售和工业生产预计也将放缓。</blockquote></p><p> “There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p><p><blockquote>荷兰银行高级能源经济学家Hans van Cleef表示：“中国数据疲软，但欧洲德尔塔变异毒株的上升也引发了人们对需求复苏的一些怀疑。”</blockquote></p><p> The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p><p><blockquote>德尔塔变异毒株已经蔓延到世界各地，包括自5月中旬以来报告病例最多的美国。在欧洲，英国和法国官员正在就新病例和重新开放发出警告。</blockquote></p><p> Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p><p><blockquote>欧佩克+即将供应的不确定性继续笼罩着市场。在成员国之间就减产发生争执后，该联盟上周放弃了会议，一周后，仍未达成协议。</blockquote></p><p> “They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p><p><blockquote>Again Capital LLC的基尔达夫表示：“他们将在一定程度上提高，这只是幅度以及是否会崩溃的问题。”</blockquote></p><p> The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p><p><blockquote>国际能源署将于周二发布月度报告，为投资者提供市场概况，而OPEC将于周四发布自己的月度报告。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1,"symbols_score_info":{"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142064787,"gmtCreate":1626104877449,"gmtModify":1631889244216,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142064787","repostId":"1143990601","repostType":4,"isVote":1,"tweetType":1,"viewCount":1308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114481303,"gmtCreate":1623087740802,"gmtModify":1631889244259,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/114481303","repostId":"1133110564","repostType":4,"repost":{"id":"1133110564","kind":"news","pubTimestamp":1623080895,"share":"https://www.laohu8.com/m/news/1133110564?lang=zh_CN&edition=full","pubTime":"2021-06-07 23:48","market":"us","language":"en","title":"Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健(Biogen)阿尔茨海默病药物获得FDA批准</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133110564","media":"zerohedge","summary":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's ","content":"<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p><p><blockquote>FDA周一批准了Biogen用于治疗阿尔茨海默氏症生理原因的实验药物Aduhelm（aducanumab），作为第一种解决该疾病潜在原因的治疗方法，尽管该药物的临床试验结果明显好坏参半。</blockquote></p><p> AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p><p><blockquote>正如路透社解释的那样，Aduhelm是一长串药物之一，这些药物旨在清除早期阿尔茨海默氏症患者大脑中一种称为β淀粉样蛋白的蛋白质的粘性沉积物，以避免这种疾病最严重的破坏，这种疾病的特点是严重的记忆丧失和生活自理能力的丧失。</blockquote></p><p> The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p><p><blockquote>Aduhelm的临床试验首次表明，这些斑块（被认为是该疾病的标志性症状）的减少可以减缓患者的临床衰退。</blockquote></p><p> The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p><p><blockquote>FDA的新闻稿中提到，该药物在专业界造成了裂痕：该机构表示，Biogen提交的数据（来自两项3期临床试验）“非常复杂，在临床益处方面留下了残余的不确定性。关于Aduhelm是否应该被批准，公众存在相当大的争论。正如在解释科学数据时经常出现的情况一样，专家群体提供了不同的观点。”许多科学家反对该药物的批准，称其不起作用。</blockquote></p><p> As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p><p><blockquote>因此，Biogen将被要求进行另一轮批准后临床研究（FDA称之为“4期”试验）。</blockquote></p><p> Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p><p><blockquote>Biogen的新药是自2003年以来首个获批的阿尔茨海默病治疗药物。该疾病的现有治疗课程并没有多大作用来阻止潜在的原因，而是旨在让患者更舒适。</blockquote></p><p> FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p><p><blockquote>FDA批准Aduhelm使用加速批准途径治疗阿尔茨海默病患者，由于该药物在减少β淀粉样蛋白脑斑块方面取得了成功，因此获得了批准。</blockquote></p><p> Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p><p><blockquote>消息传出后，百健(Biogen)的股价上涨，其他已知致力于阿尔茨海默氏症治疗的公司的股价也上涨，其中包括百健(Biogen)的竞争对手礼来公司(Eli Lilly)。纳斯达克生物科技指数攀升至盘中高点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p><p><blockquote><u><b>阅读下面的完整新闻稿：</b></u></blockquote></p><p> <i>Today FDA approved&nbsp;Aduhelm (aducanumab)&nbsp;to treat patients with Alzheimer’s disease using the&nbsp;Accelerated Approval&nbsp;pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p><p><blockquote><i>今天，FDA批准Aduhelm（aducanumab）使用加速批准途径治疗阿尔茨海默病患者，根据该途径，FDA批准一种治疗严重或危及生命疾病的药物，当该药物被证明对替代终点有影响时，该药物可能比现有治疗提供有意义的治疗益处，该终点有合理的可能性预测患者的临床益处，并且该药物的临床益处仍存在一些不确定性。</i></blockquote></p><p> <i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.&nbsp; The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p><p><blockquote><i>这一批准在许多方面都意义重大。Aduhelm是自2003年以来首个被批准用于治疗阿尔茨海默病的新型疗法。也许更重要的是，Aduhelm是第一个针对阿尔茨海默病潜在病理生理学的治疗方法，即大脑中淀粉样β斑块的存在。Aduhelm的临床试验首次表明，这些斑块的减少——这是阿尔茨海默病患者大脑中的标志性发现——有望导致这种毁灭性痴呆症的临床下降减少。</i></blockquote></p><p> <i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p><p><blockquote><i>我们很清楚围绕这一批准的关注。我们知道Aduhelm已经引起了媒体、阿尔茨海默氏症患者群体、我们当选的官员和其他感兴趣的利益相关者的关注。随着一种严重的、危及生命的疾病的治疗悬而未决，这么多人关注这次审查的结果是有道理的。此外，申请人提交的数据非常复杂，并留下了关于临床获益的剩余不确定性。关于Aduhelm是否应该获得批准，公众进行了大量辩论。正如解释科学数据时经常出现的情况一样，专家群体提供了不同的观点。</i></blockquote></p><p></p><p> <i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the&nbsp;Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p><p><blockquote><i>归根结底，在数据不直观的情况下做出监管决策时，我们遵循了通常的行动方针。我们仔细检查了临床试验结果，征求了外周和中枢神经系统药物咨询委员会的意见，听取了患者群体的观点，并审查了所有相关数据。我们最终决定使用加速批准途径——该途径旨在为患有严重疾病的患者提供更早获得潜在有价值的治疗，这些患者的需求未得到满足，并且尽管该益处仍存在一些剩余的不确定性，但仍有望获得临床益处。在确定该申请符合加速批准的要求时，该机构得出结论，Aduhelm对阿尔茨海默病患者的益处超过了该疗法的风险。</i></blockquote></p><p> <i><b>What the Data Show</b></i></p><p><blockquote><i><b>数据显示了什么</b></i></blockquote></p><p> <i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. &nbsp;In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. &nbsp;It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p><p><blockquote><i>Aduhelm的后期开发计划包括两项3期临床试验。一项研究达到了主要终点，显示临床下降减少。第二项试验未达到主要终点。然而，在所有对其进行评估的研究中，Aduhelm以剂量和时间依赖性方式持续且非常令人信服地降低了大脑中淀粉样蛋白斑块的水平。预计淀粉样斑块的减少将导致临床下降的减少。</i></blockquote></p><p> <i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p><p><blockquote><i>我们知道，于2020年11月召开会议审查临床试验数据并讨论支持Aduhelm申请的证据的外周和中枢神经系统药物咨询委员会并不同意将one成功试验的临床获益视为支持批准的主要证据是合理的。咨询委员会没有讨论加速核准的备选办法。如上所述，在所有试验中都清楚地表明，用Aduhelm治疗可显著减少β淀粉样蛋白斑块。斑块的这种减少很可能导致临床益处。在咨询委员会提供反馈后，我们继续进行审查和审议，我们决定Aduhelm申请中提出的证据符合加速批准的标准。我们感谢咨询委员会对数据的独立审查和宝贵意见。</i></blockquote></p><p> <i><b>Accelerated Approval</b></i></p><p><blockquote><i><b>加速审批</b></i></blockquote></p><p> <i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.&nbsp; Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).&nbsp; A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p><p><blockquote><i>FDA制定了加速批准计划，以允许更早批准治疗严重疾病和满足未满足的医疗需求的药物。批准基于替代或中间临床终点（在这种情况下，大脑中淀粉样斑块的减少）。替代终点是一种标记，如实验室测量、射线照相图像、体征或其他被认为预测临床益处但其本身不是临床益处的测量。替代终点的使用可以大大缩短获得FDA批准之前所需的时间。</i></blockquote></p><p> <i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p><p><blockquote><i>制药公司需要进行批准后研究，以验证预期的临床益处。这些研究被称为4期验证性试验。如果验证性试验未能验证该药物的预期临床益处，FDA已制定监管程序，可能会导致该药物退出市场。</i></blockquote></p><p> <i><b>The Devastation of Alzheimer’s Disease</b></i></p><p><blockquote><i><b>阿尔茨海默病的破坏</b></i></blockquote></p><p> <i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p><p><blockquote><i>综上所述，我们非常清楚阿尔茨海默病造成的逐渐和累积的破坏，因为随着时间的推移，患者会失去记忆和认知功能。在晚期疾病中，人们不再能够进行对话或对环境做出反应。平均而言，阿尔茨海默病患者在诊断后可以活4到8年，但有些患者可以活20年。</i></blockquote></p><p> <i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p><p><blockquote><i>治疗的需求是迫切的：目前，超过600万美国人患有阿尔茨海默病，随着人口老龄化，这一数字预计还会增加。阿尔茨海默氏症是美国第六大死亡原因。</i></blockquote></p><p> <i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. &nbsp;As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p><p><blockquote><i>尽管Aduhelm的临床益处数据很复杂，但FDA已经确定，有大量证据表明Aduhelm减少了大脑中的β淀粉样蛋白斑块，并且这些斑块的减少很可能预示着对患者的重要益处。由于FDA批准Aduhelm，阿尔茨海默病患者有了一种重要而关键的新疗法，可以帮助对抗这种疾病。</i></blockquote></p><p></p><p> <i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p><p><blockquote><i>FDA将继续监测Aduhelm进入市场并最终到达患者床边的情况。此外，FDA要求Biogen进行批准后临床试验，以验证该药物的临床益处。如果药物没有按预期发挥作用，我们可以采取措施将其从市场上撤下。但希望随着越来越多的人接受Aduhelm，我们将在临床试验中看到进一步的益处证据。作为一个机构，我们还将继续致力于促进这种灾难性疾病的药物开发。</i></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健(Biogen)阿尔茨海默病药物获得FDA批准</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nControversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健(Biogen)阿尔茨海默病药物获得FDA批准</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">zerohedge</strong><span class=\"h-time small\">2021-06-07 23:48</span>\n</p>\n</h4>\n</header>\n<article>\n<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p><p><blockquote>FDA周一批准了Biogen用于治疗阿尔茨海默氏症生理原因的实验药物Aduhelm（aducanumab），作为第一种解决该疾病潜在原因的治疗方法，尽管该药物的临床试验结果明显好坏参半。</blockquote></p><p> AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p><p><blockquote>正如路透社解释的那样，Aduhelm是一长串药物之一，这些药物旨在清除早期阿尔茨海默氏症患者大脑中一种称为β淀粉样蛋白的蛋白质的粘性沉积物，以避免这种疾病最严重的破坏，这种疾病的特点是严重的记忆丧失和生活自理能力的丧失。</blockquote></p><p> The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p><p><blockquote>Aduhelm的临床试验首次表明，这些斑块（被认为是该疾病的标志性症状）的减少可以减缓患者的临床衰退。</blockquote></p><p> The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p><p><blockquote>FDA的新闻稿中提到，该药物在专业界造成了裂痕：该机构表示，Biogen提交的数据（来自两项3期临床试验）“非常复杂，在临床益处方面留下了残余的不确定性。关于Aduhelm是否应该被批准，公众存在相当大的争论。正如在解释科学数据时经常出现的情况一样，专家群体提供了不同的观点。”许多科学家反对该药物的批准，称其不起作用。</blockquote></p><p> As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p><p><blockquote>因此，Biogen将被要求进行另一轮批准后临床研究（FDA称之为“4期”试验）。</blockquote></p><p> Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p><p><blockquote>Biogen的新药是自2003年以来首个获批的阿尔茨海默病治疗药物。该疾病的现有治疗课程并没有多大作用来阻止潜在的原因，而是旨在让患者更舒适。</blockquote></p><p> FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p><p><blockquote>FDA批准Aduhelm使用加速批准途径治疗阿尔茨海默病患者，由于该药物在减少β淀粉样蛋白脑斑块方面取得了成功，因此获得了批准。</blockquote></p><p> Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p><p><blockquote>消息传出后，百健(Biogen)的股价上涨，其他已知致力于阿尔茨海默氏症治疗的公司的股价也上涨，其中包括百健(Biogen)的竞争对手礼来公司(Eli Lilly)。纳斯达克生物科技指数攀升至盘中高点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p><p><blockquote><u><b>阅读下面的完整新闻稿：</b></u></blockquote></p><p> <i>Today FDA approved&nbsp;Aduhelm (aducanumab)&nbsp;to treat patients with Alzheimer’s disease using the&nbsp;Accelerated Approval&nbsp;pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p><p><blockquote><i>今天，FDA批准Aduhelm（aducanumab）使用加速批准途径治疗阿尔茨海默病患者，根据该途径，FDA批准一种治疗严重或危及生命疾病的药物，当该药物被证明对替代终点有影响时，该药物可能比现有治疗提供有意义的治疗益处，该终点有合理的可能性预测患者的临床益处，并且该药物的临床益处仍存在一些不确定性。</i></blockquote></p><p> <i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.&nbsp; The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p><p><blockquote><i>这一批准在许多方面都意义重大。Aduhelm是自2003年以来首个被批准用于治疗阿尔茨海默病的新型疗法。也许更重要的是，Aduhelm是第一个针对阿尔茨海默病潜在病理生理学的治疗方法，即大脑中淀粉样β斑块的存在。Aduhelm的临床试验首次表明，这些斑块的减少——这是阿尔茨海默病患者大脑中的标志性发现——有望导致这种毁灭性痴呆症的临床下降减少。</i></blockquote></p><p> <i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p><p><blockquote><i>我们很清楚围绕这一批准的关注。我们知道Aduhelm已经引起了媒体、阿尔茨海默氏症患者群体、我们当选的官员和其他感兴趣的利益相关者的关注。随着一种严重的、危及生命的疾病的治疗悬而未决，这么多人关注这次审查的结果是有道理的。此外，申请人提交的数据非常复杂，并留下了关于临床获益的剩余不确定性。关于Aduhelm是否应该获得批准，公众进行了大量辩论。正如解释科学数据时经常出现的情况一样，专家群体提供了不同的观点。</i></blockquote></p><p></p><p> <i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the&nbsp;Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p><p><blockquote><i>归根结底，在数据不直观的情况下做出监管决策时，我们遵循了通常的行动方针。我们仔细检查了临床试验结果，征求了外周和中枢神经系统药物咨询委员会的意见，听取了患者群体的观点，并审查了所有相关数据。我们最终决定使用加速批准途径——该途径旨在为患有严重疾病的患者提供更早获得潜在有价值的治疗，这些患者的需求未得到满足，并且尽管该益处仍存在一些剩余的不确定性，但仍有望获得临床益处。在确定该申请符合加速批准的要求时，该机构得出结论，Aduhelm对阿尔茨海默病患者的益处超过了该疗法的风险。</i></blockquote></p><p> <i><b>What the Data Show</b></i></p><p><blockquote><i><b>数据显示了什么</b></i></blockquote></p><p> <i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. &nbsp;In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. &nbsp;It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p><p><blockquote><i>Aduhelm的后期开发计划包括两项3期临床试验。一项研究达到了主要终点，显示临床下降减少。第二项试验未达到主要终点。然而，在所有对其进行评估的研究中，Aduhelm以剂量和时间依赖性方式持续且非常令人信服地降低了大脑中淀粉样蛋白斑块的水平。预计淀粉样斑块的减少将导致临床下降的减少。</i></blockquote></p><p> <i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p><p><blockquote><i>我们知道，于2020年11月召开会议审查临床试验数据并讨论支持Aduhelm申请的证据的外周和中枢神经系统药物咨询委员会并不同意将one成功试验的临床获益视为支持批准的主要证据是合理的。咨询委员会没有讨论加速核准的备选办法。如上所述，在所有试验中都清楚地表明，用Aduhelm治疗可显著减少β淀粉样蛋白斑块。斑块的这种减少很可能导致临床益处。在咨询委员会提供反馈后，我们继续进行审查和审议，我们决定Aduhelm申请中提出的证据符合加速批准的标准。我们感谢咨询委员会对数据的独立审查和宝贵意见。</i></blockquote></p><p> <i><b>Accelerated Approval</b></i></p><p><blockquote><i><b>加速审批</b></i></blockquote></p><p> <i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.&nbsp; Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).&nbsp; A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p><p><blockquote><i>FDA制定了加速批准计划，以允许更早批准治疗严重疾病和满足未满足的医疗需求的药物。批准基于替代或中间临床终点（在这种情况下，大脑中淀粉样斑块的减少）。替代终点是一种标记，如实验室测量、射线照相图像、体征或其他被认为预测临床益处但其本身不是临床益处的测量。替代终点的使用可以大大缩短获得FDA批准之前所需的时间。</i></blockquote></p><p> <i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p><p><blockquote><i>制药公司需要进行批准后研究，以验证预期的临床益处。这些研究被称为4期验证性试验。如果验证性试验未能验证该药物的预期临床益处，FDA已制定监管程序，可能会导致该药物退出市场。</i></blockquote></p><p> <i><b>The Devastation of Alzheimer’s Disease</b></i></p><p><blockquote><i><b>阿尔茨海默病的破坏</b></i></blockquote></p><p> <i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p><p><blockquote><i>综上所述，我们非常清楚阿尔茨海默病造成的逐渐和累积的破坏，因为随着时间的推移，患者会失去记忆和认知功能。在晚期疾病中，人们不再能够进行对话或对环境做出反应。平均而言，阿尔茨海默病患者在诊断后可以活4到8年，但有些患者可以活20年。</i></blockquote></p><p> <i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p><p><blockquote><i>治疗的需求是迫切的：目前，超过600万美国人患有阿尔茨海默病，随着人口老龄化，这一数字预计还会增加。阿尔茨海默氏症是美国第六大死亡原因。</i></blockquote></p><p> <i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. &nbsp;As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p><p><blockquote><i>尽管Aduhelm的临床益处数据很复杂，但FDA已经确定，有大量证据表明Aduhelm减少了大脑中的β淀粉样蛋白斑块，并且这些斑块的减少很可能预示着对患者的重要益处。由于FDA批准Aduhelm，阿尔茨海默病患者有了一种重要而关键的新疗法，可以帮助对抗这种疾病。</i></blockquote></p><p></p><p> <i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p><p><blockquote><i>FDA将继续监测Aduhelm进入市场并最终到达患者床边的情况。此外，FDA要求Biogen进行批准后临床试验，以验证该药物的临床益处。如果药物没有按预期发挥作用，我们可以采取措施将其从市场上撤下。但希望随着越来越多的人接受Aduhelm，我们将在临床试验中看到进一步的益处证据。作为一个机构，我们还将继续致力于促进这种灾难性疾病的药物开发。</i></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">zerohedge</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133110564","content_text":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.\nAsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.\nThe clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.\nThe drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.\nAs a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).\nBiogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.\nFDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.\nShares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.\nRead the full press release below:\nToday FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.\nThis approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.  The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.\nWe are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\nAt the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.\nWhat the Data Show\nThe late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint.  In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion.  It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.\nWe know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.\nAccelerated Approval\nThe FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.  Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).  A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.\nDrug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.\nThe Devastation of Alzheimer’s Disease\nWith all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.\nThe need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.\nAlthough the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients.  As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.\nFDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":2487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":118594655,"gmtCreate":1622736920377,"gmtModify":1631889244270,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118594655","repostId":"2140247164","repostType":4,"isVote":1,"tweetType":1,"viewCount":1854,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111320436,"gmtCreate":1622653635125,"gmtModify":1631889244285,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111320436","repostId":"2140448417","repostType":4,"isVote":1,"tweetType":1,"viewCount":2796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111963117,"gmtCreate":1622649396339,"gmtModify":1631889244292,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".&nbsp;","listText":".&nbsp;","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111963117","repostId":"1188552613","repostType":4,"repost":{"id":"1188552613","kind":"news","pubTimestamp":1622627641,"share":"https://www.laohu8.com/m/news/1188552613?lang=zh_CN&edition=full","pubTime":"2021-06-02 17:54","market":"us","language":"en","title":"AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC股价再次飙升。如何理解这一举动。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188552613","media":"Barrons","summary":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, th","content":"<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of&nbsp;GameStop&nbsp;and&nbsp;BlackBerry&nbsp;into speculative territory.</p><p><blockquote>AMC院线股价飙升很容易被视为迷因交易疯狂，社交媒体推动的投资者狂热将游戏驿站和黑莓等公司带入了投机领域。</blockquote></p><p> But it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.</p><p><blockquote>但传统投资者可能错过了电影院业务的根本性变化——而且这已经不是第一次了。</blockquote></p><p> Shares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office.&nbsp;Shares were up another 34%, to $42.92, in premarket trading Wednesday.</p><p><blockquote>AMC（股票代码：AMC）股价周二飙升23%，收于32.04美元，略低于5月底创下的36.72美元的历史高点。这使得这家连锁影院的市值约为160亿美元，是2018年票房破纪录的一年的15倍多。周三盘前交易中，该公司股价又上涨34%，至42.92美元。</blockquote></p><p> Even if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.</p><p><blockquote>不过，即使投资者错过了拐点，数学也不成立。原因可能是市值不是正确的衡量标准。也许是企业价值，本质上是市值和债务。AMC的企业价值约为260亿美元，而2018年底为62亿美元左右。</blockquote></p><p> AMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.</p><p><blockquote>AMC在疫情期间增加了债务，因为该国最大城市的影院连续几个月处于黑暗之中。这些数字很容易理解原因：2020年美国票房收入约为21亿美元，比2018年创纪录的119亿美元下降了81%。</blockquote></p><p> So, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.</p><p><blockquote>因此，投资者似乎对电影院经济感到恼火。但这不是第一次了。这个行业在世纪之交基本上破产了。例如，富豪影院于2001年宣布破产。</blockquote></p><p> Back then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.</p><p><blockquote>当时，该行业有足够的容量，因为一种新的剧院设计——体育场座位可以更好地观看屏幕。这种转变意味着连锁电影院必须翻新，否则就有可能失去所有顾客到视野更好的电影院。最终，太多的座位和不够的顾客意味着体育场座位投资的回报从未实现。</blockquote></p><p> The upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&amp;P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.</p><p><blockquote>结果是整合。随着操作员的减少，屏幕数量稳定下来。2002年至2007年间，Regal Cinemas因股票定价错误而成为现金产生机器。该股平均每年回报率为21%。同期，标普500和道琼斯工业平均指数的平均年回报率均低于9%。</blockquote></p><p> In those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.</p><p><blockquote>当年，富豪影院的企业价值约为50亿美元，约占美国票房总收入的50%。这与今天的AMC相去甚远。新的东西必须与众不同，AMC才值得。</blockquote></p><p> Maybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.</p><p><blockquote>也许电影院业务又要经历一段盘整期，可以迎来又一个回报的黄金时代。事实上，AMC周二的上涨是由筹集的新资本推动的，因此该公司可以继续进攻，收购已倒闭的连锁店。毕竟，垄断有利于股票回报。</blockquote></p><p> If AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.</p><p><blockquote>如果AMC能够增加市场份额，并且美国票房销售额能够在几年内恢复到2018年的水平，那么总销售额可能会达到90亿美元——60亿美元来自门票，30亿美元来自特许经营。2018年销售额达55亿美元。</blockquote></p><p> Then, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&amp;P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.</p><p><blockquote>然后，随着规模的扩大带来更好的毛利率，AMC每年可能能够产生6亿美元的自由现金流，这使得该股的自由现金流收益率约为4%。标普500的自由现金流收益率约为3%。这些数字可以发挥作用——如果它们被拉伸的话。</blockquote></p><p> There are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.</p><p><blockquote>不过，这种情况存在问题。有很多如果和可能——AMC过去从未产生过这样的现金流。达到6亿美元的自由现金流更多的是为了证明当前估值的合理性，而不是预测可能发生的情况。</blockquote></p><p> Also, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.</p><p><blockquote>此外，通过并购，AMC的市场份额可能会上升，但仍然存在竞争对手。富豪影院仍然存在，归电影世界控股公司所有。伦敦）。喜满客（CNK）也是如此。没有真正的垄断。</blockquote></p><p> AMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.</p><p><blockquote>AMC及其同行也必须应对流媒体问题。独家影院放映的窗口正在缩小。疫情加速了这一点。如果AMC变得太大，对电影制作人的要求太高，人才总是可以更快地转向流媒体，从而损害票房销售。</blockquote></p><p> There is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.</p><p><blockquote>还有同行股票的问题。他们并不认为这是剧院的一个勇敢的新世界。Cineworld股价较52周低点上涨484%，但仍较历史高点下跌72%。喜满客股价较52周低点上涨222%。它们比历史高点下跌了47%。</blockquote></p><p> AMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.</p><p><blockquote>AMC股价再次较52周低点上涨近1,600%，较5月份历史高点仅下跌13%。</blockquote></p><p> Wall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.</p><p><blockquote>华尔街也没有看到潜力。九名分析师关注该股。分析师平均目标价约为5美元。在疫情爆发之前，分析师的平均目标价为15美元。但当时股票较少。旧的目标企业价值约为70亿美元。很难从70亿美元增加到260亿美元来预测更好的利润率。</blockquote></p><p></p><p> Analysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.</p><p><blockquote>不过，分析师确实模拟了正自由现金流——2022年为1300万美元，2023年为9000万美元。这距离6亿美元还有很长的路要走。</blockquote></p><p> And that’s just another way of saying that AMC bulls are a long way from making the math work.</p><p><blockquote>这只是AMC多头距离实现数学计算还有很长的路要走的另一种说法。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC股价再次飙升。如何理解这一举动。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC股价再次飙升。如何理解这一举动。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-06-02 17:54</span>\n</p>\n</h4>\n</header>\n<article>\n<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of&nbsp;GameStop&nbsp;and&nbsp;BlackBerry&nbsp;into speculative territory.</p><p><blockquote>AMC院线股价飙升很容易被视为迷因交易疯狂，社交媒体推动的投资者狂热将游戏驿站和黑莓等公司带入了投机领域。</blockquote></p><p> But it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.</p><p><blockquote>但传统投资者可能错过了电影院业务的根本性变化——而且这已经不是第一次了。</blockquote></p><p> Shares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office.&nbsp;Shares were up another 34%, to $42.92, in premarket trading Wednesday.</p><p><blockquote>AMC（股票代码：AMC）股价周二飙升23%，收于32.04美元，略低于5月底创下的36.72美元的历史高点。这使得这家连锁影院的市值约为160亿美元，是2018年票房破纪录的一年的15倍多。周三盘前交易中，该公司股价又上涨34%，至42.92美元。</blockquote></p><p> Even if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.</p><p><blockquote>不过，即使投资者错过了拐点，数学也不成立。原因可能是市值不是正确的衡量标准。也许是企业价值，本质上是市值和债务。AMC的企业价值约为260亿美元，而2018年底为62亿美元左右。</blockquote></p><p> AMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.</p><p><blockquote>AMC在疫情期间增加了债务，因为该国最大城市的影院连续几个月处于黑暗之中。这些数字很容易理解原因：2020年美国票房收入约为21亿美元，比2018年创纪录的119亿美元下降了81%。</blockquote></p><p> So, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.</p><p><blockquote>因此，投资者似乎对电影院经济感到恼火。但这不是第一次了。这个行业在世纪之交基本上破产了。例如，富豪影院于2001年宣布破产。</blockquote></p><p> Back then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.</p><p><blockquote>当时，该行业有足够的容量，因为一种新的剧院设计——体育场座位可以更好地观看屏幕。这种转变意味着连锁电影院必须翻新，否则就有可能失去所有顾客到视野更好的电影院。最终，太多的座位和不够的顾客意味着体育场座位投资的回报从未实现。</blockquote></p><p> The upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&amp;P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.</p><p><blockquote>结果是整合。随着操作员的减少，屏幕数量稳定下来。2002年至2007年间，Regal Cinemas因股票定价错误而成为现金产生机器。该股平均每年回报率为21%。同期，标普500和道琼斯工业平均指数的平均年回报率均低于9%。</blockquote></p><p> In those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.</p><p><blockquote>当年，富豪影院的企业价值约为50亿美元，约占美国票房总收入的50%。这与今天的AMC相去甚远。新的东西必须与众不同，AMC才值得。</blockquote></p><p> Maybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.</p><p><blockquote>也许电影院业务又要经历一段盘整期，可以迎来又一个回报的黄金时代。事实上，AMC周二的上涨是由筹集的新资本推动的，因此该公司可以继续进攻，收购已倒闭的连锁店。毕竟，垄断有利于股票回报。</blockquote></p><p> If AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.</p><p><blockquote>如果AMC能够增加市场份额，并且美国票房销售额能够在几年内恢复到2018年的水平，那么总销售额可能会达到90亿美元——60亿美元来自门票，30亿美元来自特许经营。2018年销售额达55亿美元。</blockquote></p><p> Then, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&amp;P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.</p><p><blockquote>然后，随着规模的扩大带来更好的毛利率，AMC每年可能能够产生6亿美元的自由现金流，这使得该股的自由现金流收益率约为4%。标普500的自由现金流收益率约为3%。这些数字可以发挥作用——如果它们被拉伸的话。</blockquote></p><p> There are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.</p><p><blockquote>不过，这种情况存在问题。有很多如果和可能——AMC过去从未产生过这样的现金流。达到6亿美元的自由现金流更多的是为了证明当前估值的合理性，而不是预测可能发生的情况。</blockquote></p><p> Also, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.</p><p><blockquote>此外，通过并购，AMC的市场份额可能会上升，但仍然存在竞争对手。富豪影院仍然存在，归电影世界控股公司所有。伦敦）。喜满客（CNK）也是如此。没有真正的垄断。</blockquote></p><p> AMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.</p><p><blockquote>AMC及其同行也必须应对流媒体问题。独家影院放映的窗口正在缩小。疫情加速了这一点。如果AMC变得太大，对电影制作人的要求太高，人才总是可以更快地转向流媒体，从而损害票房销售。</blockquote></p><p> There is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.</p><p><blockquote>还有同行股票的问题。他们并不认为这是剧院的一个勇敢的新世界。Cineworld股价较52周低点上涨484%，但仍较历史高点下跌72%。喜满客股价较52周低点上涨222%。它们比历史高点下跌了47%。</blockquote></p><p> AMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.</p><p><blockquote>AMC股价再次较52周低点上涨近1,600%，较5月份历史高点仅下跌13%。</blockquote></p><p> Wall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.</p><p><blockquote>华尔街也没有看到潜力。九名分析师关注该股。分析师平均目标价约为5美元。在疫情爆发之前，分析师的平均目标价为15美元。但当时股票较少。旧的目标企业价值约为70亿美元。很难从70亿美元增加到260亿美元来预测更好的利润率。</blockquote></p><p></p><p> Analysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.</p><p><blockquote>不过，分析师确实模拟了正自由现金流——2022年为1300万美元，2023年为9000万美元。这距离6亿美元还有很长的路要走。</blockquote></p><p> And that’s just another way of saying that AMC bulls are a long way from making the math work.</p><p><blockquote>这只是AMC多头距离实现数学计算还有很长的路要走的另一种说法。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188552613","content_text":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into speculative territory.\nBut it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.\nShares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office. Shares were up another 34%, to $42.92, in premarket trading Wednesday.\nEven if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.\nAMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.\nSo, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.\nBack then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.\nThe upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.\nIn those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.\nMaybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.\nIf AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.\nThen, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.\nThere are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.\nAlso, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.\nAMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.\nThere is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.\nAMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.\nWall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.\nAnalysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.\nAnd that’s just another way of saying that AMC bulls are a long way from making the math work.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":2624,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119454643,"gmtCreate":1622560637282,"gmtModify":1631889244304,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119454643","repostId":"2140617694","repostType":4,"isVote":1,"tweetType":1,"viewCount":1950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119455704,"gmtCreate":1622560602508,"gmtModify":1631889244319,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":"Weeee","listText":"Weeee","text":"Weeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119455704","repostId":"2138889344","repostType":4,"repost":{"id":"2138889344","kind":"news","pubTimestamp":1622546894,"share":"https://www.laohu8.com/m/news/2138889344?lang=zh_CN&edition=full","pubTime":"2021-06-01 19:28","market":"us","language":"en","title":"Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将报告第一季度收益：前景如何？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2138889344","media":"Zacks","summary":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarte","content":"<p><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</b> is set to report first-quarter fiscal 2022 results on Jun 1.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a>视频通信</b>定于6月1日公布2022财年第一季度业绩。</blockquote></p><p>For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.</p><p><blockquote>该公司预计本季度非GAAP每股收益在95美分至97美分之间。总收入预计在9亿美元至9.05亿美元之间。</blockquote></p><p>The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.</p><p><blockquote>过去30天，Zacks对收益的一致预期保持在每股97美分。该公司报告去年同期每股收益为20美分。</blockquote></p><p>The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.</p><p><blockquote>收入的共识为9.052亿美元，比去年同期报告的数字增长175.8%。</blockquote></p><p><h3>Zoom Video Communications, Inc. Price and EPS Surprise</h3><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc75f53073be8992ce4f8cf58d4ebd0a\" tg-width=\"539\" tg-height=\"264\"><span>Zoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. Quote</span></p><p><blockquote><h3>Zoom Video通信公司。价格和每股收益惊喜</h3><p class=\"t-img-caption\"><span>Zoom Video通信公司价格-每股收益-惊喜|Zoom Video通信公司报价</span></p></blockquote></p><p>Zoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.</p><p><blockquote>Zoom的收益在过去四个季度都超过了Zacks的普遍预期，平均意外率为73.2%。</blockquote></p><p>Let’s see how things have shaped up for this announcement.</p><p><blockquote>让我们看看这个公告的进展如何。</blockquote></p><p><h3>Factors to Watch</h3>Zoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.</p><p><blockquote><h3>值得关注的因素</h3>尽管开展了疫苗接种活动，但Zoom第一财季的收入预计仍将受益于冠状病毒引发的在家工作和在线学习浪潮。</blockquote></p><p>Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.</p><p><blockquote>值得注意的是，该公司的免费增值商业模式帮助其快速赢得客户，然后可以将这些客户转化为付费客户。2021财年第四季度，过去12个月的美元净增长率超过156%。预计这一势头将在即将报告的季度持续下去。</blockquote></p><p>Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.</p><p><blockquote>此外，支持商务专业人士远程工作的Zoom For Home的可用性是一个关键的催化剂。</blockquote></p><p>Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of <b>Atlassian</b>, <b><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a></b> and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</p><p><blockquote>此外，这家Zacks排名第二（购买）的公司拥有强大的合作伙伴基础，其中包括<b>Atlassian</b>,<b><a href=\"https://laohu8.com/S/NOW\">服务现在</a></b>和Dropbox，预计将使该公司在第一财季赢得企业客户方面受益。你可以在这里看到今天咤克斯排名第一（强力买入）股票的完整列表。</blockquote></p><p>However, Zoom Video continues to face significant competition from the likes of <b>Cisco</b>, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.</p><p><blockquote>然而，Zoom Video继续面临来自以下公司的激烈竞争<b>思科</b>、微软和谷歌相遇。这可能会导致中小型企业客户的流失，从而可能会损害营收增长。</blockquote></p><p><h3>Key Q1 Highlights</h3>During the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.</p><p><blockquote><h3>第一季度主要亮点</h3>在即将报告的季度中，Zoom宣布了一项名为Zoom Apps Fund的1亿美元风险基金，旨在刺激Zoom的Zoom应用、集成、开发者平台和硬件生态系统的增长。</blockquote></p><p>Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.</p><p><blockquote>此外，在本季度，Zoom和一级方程式宣布，他们已在即将到来的2021年国际汽联一级方程式世界锦标赛赛季及以后建立了新的广泛的多年合作伙伴关系。</blockquote></p><p>Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.</p><p><blockquote>此外，在2月份，Zoom宣布推出Zoom Rooms，这将帮助组织安全地重新进入办公室，并维持“无处不在的员工”。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将报告第一季度收益：前景如何？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将报告第一季度收益：前景如何？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Zacks</strong><span class=\"h-time small\">2021-06-01 19:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</b> is set to report first-quarter fiscal 2022 results on Jun 1.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a>视频通信</b>定于6月1日公布2022财年第一季度业绩。</blockquote></p><p>For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.</p><p><blockquote>该公司预计本季度非GAAP每股收益在95美分至97美分之间。总收入预计在9亿美元至9.05亿美元之间。</blockquote></p><p>The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.</p><p><blockquote>过去30天，Zacks对收益的一致预期保持在每股97美分。该公司报告去年同期每股收益为20美分。</blockquote></p><p>The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.</p><p><blockquote>收入的共识为9.052亿美元，比去年同期报告的数字增长175.8%。</blockquote></p><p><h3>Zoom Video Communications, Inc. Price and EPS Surprise</h3><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc75f53073be8992ce4f8cf58d4ebd0a\" tg-width=\"539\" tg-height=\"264\"><span>Zoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. Quote</span></p><p><blockquote><h3>Zoom Video通信公司。价格和每股收益惊喜</h3><p class=\"t-img-caption\"><span>Zoom Video通信公司价格-每股收益-惊喜|Zoom Video通信公司报价</span></p></blockquote></p><p>Zoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.</p><p><blockquote>Zoom的收益在过去四个季度都超过了Zacks的普遍预期，平均意外率为73.2%。</blockquote></p><p>Let’s see how things have shaped up for this announcement.</p><p><blockquote>让我们看看这个公告的进展如何。</blockquote></p><p><h3>Factors to Watch</h3>Zoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.</p><p><blockquote><h3>值得关注的因素</h3>尽管开展了疫苗接种活动，但Zoom第一财季的收入预计仍将受益于冠状病毒引发的在家工作和在线学习浪潮。</blockquote></p><p>Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.</p><p><blockquote>值得注意的是，该公司的免费增值商业模式帮助其快速赢得客户，然后可以将这些客户转化为付费客户。2021财年第四季度，过去12个月的美元净增长率超过156%。预计这一势头将在即将报告的季度持续下去。</blockquote></p><p>Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.</p><p><blockquote>此外，支持商务专业人士远程工作的Zoom For Home的可用性是一个关键的催化剂。</blockquote></p><p>Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of <b>Atlassian</b>, <b><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a></b> and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</p><p><blockquote>此外，这家Zacks排名第二（购买）的公司拥有强大的合作伙伴基础，其中包括<b>Atlassian</b>,<b><a href=\"https://laohu8.com/S/NOW\">服务现在</a></b>和Dropbox，预计将使该公司在第一财季赢得企业客户方面受益。你可以在这里看到今天咤克斯排名第一（强力买入）股票的完整列表。</blockquote></p><p>However, Zoom Video continues to face significant competition from the likes of <b>Cisco</b>, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.</p><p><blockquote>然而，Zoom Video继续面临来自以下公司的激烈竞争<b>思科</b>、微软和谷歌相遇。这可能会导致中小型企业客户的流失，从而可能会损害营收增长。</blockquote></p><p><h3>Key Q1 Highlights</h3>During the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.</p><p><blockquote><h3>第一季度主要亮点</h3>在即将报告的季度中，Zoom宣布了一项名为Zoom Apps Fund的1亿美元风险基金，旨在刺激Zoom的Zoom应用、集成、开发者平台和硬件生态系统的增长。</blockquote></p><p>Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.</p><p><blockquote>此外，在本季度，Zoom和一级方程式宣布，他们已在即将到来的2021年国际汽联一级方程式世界锦标赛赛季及以后建立了新的广泛的多年合作伙伴关系。</blockquote></p><p>Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.</p><p><blockquote>此外，在2月份，Zoom宣布推出Zoom Rooms，这将帮助组织安全地重新进入办公室，并维持“无处不在的员工”。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568\">Zacks</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"source_url":"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138889344","content_text":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.Zoom Video Communications, Inc. Price and EPS SurpriseZoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. QuoteZoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.Let’s see how things have shaped up for this announcement.Factors to WatchZoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of Atlassian, ServiceNow and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.However, Zoom Video continues to face significant competition from the likes of Cisco, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.Key Q1 HighlightsDuring the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.","news_type":1,"symbols_score_info":{"ZM":0.9}},"isVote":1,"tweetType":1,"viewCount":2709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134326282,"gmtCreate":1622209102946,"gmtModify":1631889244334,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/134326282","repostId":"2138107027","repostType":4,"isVote":1,"tweetType":1,"viewCount":3279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135084783,"gmtCreate":1622122701142,"gmtModify":1631889244340,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".guu ya n","listText":".guu ya n","text":".guu ya n","images":[{"img":"https://static.tigerbbs.com/f718b1732852edbe5f41671c8998e94e","width":"1125","height":"3282"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/135084783","isVote":1,"tweetType":1,"viewCount":2794,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":135086323,"gmtCreate":1622122619562,"gmtModify":1631892032979,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/135086323","repostId":"2138912120","repostType":4,"isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136463833,"gmtCreate":1622036288122,"gmtModify":1631892032982,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/136463833","repostId":"2138105101","repostType":4,"isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130340023,"gmtCreate":1621515459662,"gmtModify":1631892032985,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/130340023","repostId":"1125677133","repostType":4,"isVote":1,"tweetType":1,"viewCount":568,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":194835491,"gmtCreate":1621352496813,"gmtModify":1631892032990,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/194835491","repostId":"2136995492","repostType":4,"isVote":1,"tweetType":1,"viewCount":853,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":192373380,"gmtCreate":1621153405640,"gmtModify":1631892032993,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/192373380","repostId":"1163454382","repostType":4,"repost":{"id":"1163454382","kind":"news","pubTimestamp":1621004581,"share":"https://www.laohu8.com/m/news/1163454382?lang=zh_CN&edition=full","pubTime":"2021-05-14 23:03","market":"us","language":"en","title":"Why AMC Entertainment Stock Jumped Again Friday<blockquote>为什么AMC院线股价周五再次上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163454382","media":"Motley Fool","summary":"AMC investors have reason for more optimism on the heels of another capital raise.Yesterday's jump came after the company announcedit raised $428 million. First, the Centers for Disease Control and Prevention  issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.This should allow theaters to open back up at full capacity and be a desirable destination for vaccinat","content":"<p>  <b>AMC investors have reason for more optimism on the heels of another capital raise.</b>  <b>What happened</b></p><p><blockquote><b>在再次融资后，AMC投资者有理由更加乐观。</b><b>发生了什么</b></blockquote></p><p> A day after<b>AMC Entertainment Holdings</b>(NYSE:AMC)</p><p><blockquote>一天后<b>AMC院线控股</b>（纽约证券交易所代码：AMC）</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Yesterday's jump came after the company announcedit raised $428 million</p><p><blockquote>昨天的股价上涨是在该公司宣布筹集4.28亿美元后发生的</blockquote></p><p> First, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.</p><p><blockquote>首先，美国疾病控制和预防中心（CDC）发布了一份关于当前健康和安全协议的新声明，称完全接种疫苗的人可以在不戴口罩或保持身体距离的情况下恢复活动，包括在室内。</blockquote></p><p> This should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,<b>Walt Disney</b>(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.</p><p><blockquote>这将使电影院能够满负荷开放，并成为接种疫苗的电影顾客的理想目的地。同样在昨天，<b>迪斯尼</b>（纽约证券交易所股票代码：DIS）宣布了季度收益报告，首席执行官鲍勃·查佩克指出“我们工作室的产量有所增加”。虽然这对影院运营商来说是积极的，但迪士尼也报告称其流媒体服务的用户增长令人失望。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Lower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.</p><p><blockquote>流媒体订阅量的下降对影院业务来说可能是一个积极的信号。随着疫苗接种的继续推广，以及疾病预防控制中心现在正式批准在不戴口罩的情况下与人群聚集在室内，剧院的上座率可能会很快恢复。</blockquote></p><p> Vaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.</p><p><blockquote>疫苗接种将促使人们回到户外活动。在一年多的时间里，电影院可能会成为人们最喜欢的目的地。在另一次融资之后，AMC投资者可能认为这家公司终于有了一条充满希望的未来之路。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMC Entertainment Stock Jumped Again Friday<blockquote>为什么AMC院线股价周五再次上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMC Entertainment Stock Jumped Again Friday<blockquote>为什么AMC院线股价周五再次上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-05-14 23:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>AMC investors have reason for more optimism on the heels of another capital raise.</b>  <b>What happened</b></p><p><blockquote><b>在再次融资后，AMC投资者有理由更加乐观。</b><b>发生了什么</b></blockquote></p><p> A day after<b>AMC Entertainment Holdings</b>(NYSE:AMC)</p><p><blockquote>一天后<b>AMC院线控股</b>（纽约证券交易所代码：AMC）</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Yesterday's jump came after the company announcedit raised $428 million</p><p><blockquote>昨天的股价上涨是在该公司宣布筹集4.28亿美元后发生的</blockquote></p><p> First, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.</p><p><blockquote>首先，美国疾病控制和预防中心（CDC）发布了一份关于当前健康和安全协议的新声明，称完全接种疫苗的人可以在不戴口罩或保持身体距离的情况下恢复活动，包括在室内。</blockquote></p><p> This should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,<b>Walt Disney</b>(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.</p><p><blockquote>这将使电影院能够满负荷开放，并成为接种疫苗的电影顾客的理想目的地。同样在昨天，<b>迪斯尼</b>（纽约证券交易所股票代码：DIS）宣布了季度收益报告，首席执行官鲍勃·查佩克指出“我们工作室的产量有所增加”。虽然这对影院运营商来说是积极的，但迪士尼也报告称其流媒体服务的用户增长令人失望。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Lower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.</p><p><blockquote>流媒体订阅量的下降对影院业务来说可能是一个积极的信号。随着疫苗接种的继续推广，以及疾病预防控制中心现在正式批准在不戴口罩的情况下与人群聚集在室内，剧院的上座率可能会很快恢复。</blockquote></p><p> Vaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.</p><p><blockquote>疫苗接种将促使人们回到户外活动。在一年多的时间里，电影院可能会成为人们最喜欢的目的地。在另一次融资之后，AMC投资者可能认为这家公司终于有了一条充满希望的未来之路。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163454382","content_text":"AMC investors have reason for more optimism on the heels of another capital raise.\n\nWhat happened\nA day afterAMC Entertainment Holdings(NYSE:AMC)\nSo what\nYesterday's jump came after the company announcedit raised $428 million\nFirst, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.\nThis should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,Walt Disney(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.\nNow what\nLower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.\nVaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":196929972,"gmtCreate":1621006367596,"gmtModify":1631892032996,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/196929972","repostId":"1111018641","repostType":4,"repost":{"id":"1111018641","kind":"news","pubTimestamp":1621000588,"share":"https://www.laohu8.com/m/news/1111018641?lang=zh_CN&edition=full","pubTime":"2021-05-14 21:56","market":"us","language":"en","title":"Opinion: Why any stock market rally right now will be quick<blockquote>观点：为什么现在股市反弹会很快</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111018641","media":"MarketWatch","summary":"Market-timers are running with the bulls but quick to turn bearish.\n\nContrarian investors suspect th","content":"<p>  <b>Market-timers are running with the bulls but quick to turn bearish.</b>  Contrarian investors suspect that the stock market’s recent decline has run its course — for now.</p><p><blockquote><b>市场定时器与多头一起运行，但很快就转向看跌。</b>逆向投资者怀疑股市最近的下跌已经结束——就目前而言。</blockquote></p><p> That’s because these market timers, especially those who focus on the NasdaqNDX,1.07%market in particular, have become sufficiently bearish that the short-term path of least resistance has turned up. Still, it’s not clear that any new rally will have much lasting power. An even more serious U.S. market decline cannot be ruled out over the coming couple of months.</p><p><blockquote>这是因为这些市场定时器，尤其是那些关注纳斯达克NDX（尤其是1.07%市场）的市场定时器，已经变得足够看跌，以至于阻力最小的短期路径已经出现。尽管如此，尚不清楚任何新的反弹是否会产生持久的力量。不排除未来几个月美国市场会出现更严重的下滑。</blockquote></p><p> For now, the recent decline appears to have been quite modest by historical standards, smaller even than what satisfies the semi-official definition of a correction as a 10% decline. Before Thursday’s big rally, the Dow Jones Industrial AverageDJIA,0.85%had fallen around 1,200 points from its previous all-time high, or 3.4%. The S&amp;P 500SPX,0.98%was 4.0% below its high, and the Nasdaq CompositeCOMP,1.13%was down 7.8%.</p><p><blockquote>就目前而言，按照历史标准，最近的跌幅似乎相当温和，甚至小于半官方定义的10%跌幅。在周四大幅上涨之前，道琼斯工业平均指数DJIA已较之前的历史高点（即3.4%）下跌约1,200点，跌幅为0.85%。标准普尔500SPX指数(0.98%)较高点低4.0%，纳斯达克综合指数(1.13%)下跌7.8%。</blockquote></p><p> Consider how the Nasdaq-focused market timers reacted to these declines. As you can see from the chart below, their average recommended equity exposure (as represented by the Hulbert Nasdaq Newsletter Sentiment Index, or HNNSI) fell to minus 10.7%. That means that the Nasdaq-focused market timers are now recommending that their clients allocate an average of 10.7% of their equity trading portfolios to going short. As recently as April 29, this average exposure level stood at plus 83.6%.</p><p><blockquote>考虑一下关注纳斯达克的市场定时器对这些下跌的反应。从下图可以看出，他们的平均推荐股票敞口（以赫伯特·纳斯达克时事通讯情绪指数（HNNSI）为代表）降至负10.7%。这意味着专注于纳斯达克的市场定时器现在建议他们的客户将平均10.7%的股票交易投资组合分配给做空。就在4月29日，这一平均暴露水平为+83.6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d550f647619d600d419397967f7bb778\" tg-width=\"1260\" tg-height=\"928\"></p><p><blockquote></blockquote></p><p> That reflects a remarkably quick rush for the exits — 94.3 percentage points in just 10 trading sessions. In fact, out of the 5,000+ trading days since 2000, there have been only 18 — 0.3% — in which the HNNSI’s decline over the trailing 10 days was greater.</p><p><blockquote>这反映出退出的速度非常快——短短10个交易日内就退出了94.3个百分点。事实上，自2000年以来的5,000多个交易日中，只有18-0.3%，其中HNNSI在过去10天的跌幅更大。</blockquote></p><p> To appreciate the contrarian significance of this, consider that, on average following those past few occasions when the HNNSI declined by this much and this fast, the Nasdaq Composite was 5.3% higher in one month’s time.</p><p><blockquote>为了理解这一点的逆向意义，请考虑一下，在过去几次HNNSI下跌幅度如此之大、如此之快之后，纳斯达克综合指数在一个月内平均上涨了5.3%。</blockquote></p><p> Why, then, haven’t the contrarians become more bullish? The answer is also evident in the chart: The HNNSI’s plunge over the past 10 days stopped well short of the excessive bearish zone, defined as being in the bottom 10% of the historical distribution. That zone is represented by the beige-shaded box at the bottom of the chart.</p><p><blockquote>那么，为什么逆向投资者没有变得更加看涨呢？答案在图表中也很明显：HNNSI在过去10天的暴跌远低于过度看跌区域，过度看跌区域被定义为处于历史分布的底部10%。该区域由图表底部的米色阴影框表示。</blockquote></p><p> The last time the HNNSI fell into that zone was in March 2020. That was when the market’s “wall of worry” became incredibly strong and was able to support an impressive rally. That wall today is not as strong.</p><p><blockquote>HNNSI上一次落入该区域是在2020年3月。就在那时，市场的“担忧之墙”变得异常坚固，并能够支撑令人印象深刻的反弹。今天的那堵墙没有那么坚固了。</blockquote></p><p> The sentiment picture that the recent data are painting shows the market timers to be trigger-happy. They are quick to jump on the bullish bandwagon when the market rallies, and then jump on the bearish bandwagon when the market declines. As a result, both rallies and declines tend to be short-lived.</p><p><blockquote>最近的数据描绘的情绪图景显示，市场计时器乐于触发。当市场反弹时，他们会迅速加入看涨行列，然后当市场下跌时，他们会加入看跌行列。因此，无论是上涨还是下跌都往往是短暂的。</blockquote></p><p> A longer-lasting rally will require more extreme bearishness among the market timers, and for them to stubbornly hold onto their bearishness in the wake of the rally’s initial liftoff. Except for that to happen, the market to itself most likely would have to suffer a worse decline than we’ve experienced in recent days. In the meantime, enjoy this rally — while it lasts.</p><p><blockquote>更持久的反弹将需要市场计时器更加极端的看跌情绪，并且他们在反弹最初起飞后顽固地坚持看跌情绪。除非发生这种情况，否则市场本身很可能会遭受比我们最近几天经历的更严重的下跌。与此同时，享受这场反弹——趁它持续。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opinion: Why any stock market rally right now will be quick<blockquote>观点：为什么现在股市反弹会很快</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpinion: Why any stock market rally right now will be quick<blockquote>观点：为什么现在股市反弹会很快</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-05-14 21:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>Market-timers are running with the bulls but quick to turn bearish.</b>  Contrarian investors suspect that the stock market’s recent decline has run its course — for now.</p><p><blockquote><b>市场定时器与多头一起运行，但很快就转向看跌。</b>逆向投资者怀疑股市最近的下跌已经结束——就目前而言。</blockquote></p><p> That’s because these market timers, especially those who focus on the NasdaqNDX,1.07%market in particular, have become sufficiently bearish that the short-term path of least resistance has turned up. Still, it’s not clear that any new rally will have much lasting power. An even more serious U.S. market decline cannot be ruled out over the coming couple of months.</p><p><blockquote>这是因为这些市场定时器，尤其是那些关注纳斯达克NDX（尤其是1.07%市场）的市场定时器，已经变得足够看跌，以至于阻力最小的短期路径已经出现。尽管如此，尚不清楚任何新的反弹是否会产生持久的力量。不排除未来几个月美国市场会出现更严重的下滑。</blockquote></p><p> For now, the recent decline appears to have been quite modest by historical standards, smaller even than what satisfies the semi-official definition of a correction as a 10% decline. Before Thursday’s big rally, the Dow Jones Industrial AverageDJIA,0.85%had fallen around 1,200 points from its previous all-time high, or 3.4%. The S&amp;P 500SPX,0.98%was 4.0% below its high, and the Nasdaq CompositeCOMP,1.13%was down 7.8%.</p><p><blockquote>就目前而言，按照历史标准，最近的跌幅似乎相当温和，甚至小于半官方定义的10%跌幅。在周四大幅上涨之前，道琼斯工业平均指数DJIA已较之前的历史高点（即3.4%）下跌约1,200点，跌幅为0.85%。标准普尔500SPX指数(0.98%)较高点低4.0%，纳斯达克综合指数(1.13%)下跌7.8%。</blockquote></p><p> Consider how the Nasdaq-focused market timers reacted to these declines. As you can see from the chart below, their average recommended equity exposure (as represented by the Hulbert Nasdaq Newsletter Sentiment Index, or HNNSI) fell to minus 10.7%. That means that the Nasdaq-focused market timers are now recommending that their clients allocate an average of 10.7% of their equity trading portfolios to going short. As recently as April 29, this average exposure level stood at plus 83.6%.</p><p><blockquote>考虑一下关注纳斯达克的市场定时器对这些下跌的反应。从下图可以看出，他们的平均推荐股票敞口（以赫伯特·纳斯达克时事通讯情绪指数（HNNSI）为代表）降至负10.7%。这意味着专注于纳斯达克的市场定时器现在建议他们的客户将平均10.7%的股票交易投资组合分配给做空。就在4月29日，这一平均暴露水平为+83.6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d550f647619d600d419397967f7bb778\" tg-width=\"1260\" tg-height=\"928\"></p><p><blockquote></blockquote></p><p> That reflects a remarkably quick rush for the exits — 94.3 percentage points in just 10 trading sessions. In fact, out of the 5,000+ trading days since 2000, there have been only 18 — 0.3% — in which the HNNSI’s decline over the trailing 10 days was greater.</p><p><blockquote>这反映出退出的速度非常快——短短10个交易日内就退出了94.3个百分点。事实上，自2000年以来的5,000多个交易日中，只有18-0.3%，其中HNNSI在过去10天的跌幅更大。</blockquote></p><p> To appreciate the contrarian significance of this, consider that, on average following those past few occasions when the HNNSI declined by this much and this fast, the Nasdaq Composite was 5.3% higher in one month’s time.</p><p><blockquote>为了理解这一点的逆向意义，请考虑一下，在过去几次HNNSI下跌幅度如此之大、如此之快之后，纳斯达克综合指数在一个月内平均上涨了5.3%。</blockquote></p><p> Why, then, haven’t the contrarians become more bullish? The answer is also evident in the chart: The HNNSI’s plunge over the past 10 days stopped well short of the excessive bearish zone, defined as being in the bottom 10% of the historical distribution. That zone is represented by the beige-shaded box at the bottom of the chart.</p><p><blockquote>那么，为什么逆向投资者没有变得更加看涨呢？答案在图表中也很明显：HNNSI在过去10天的暴跌远低于过度看跌区域，过度看跌区域被定义为处于历史分布的底部10%。该区域由图表底部的米色阴影框表示。</blockquote></p><p> The last time the HNNSI fell into that zone was in March 2020. That was when the market’s “wall of worry” became incredibly strong and was able to support an impressive rally. That wall today is not as strong.</p><p><blockquote>HNNSI上一次落入该区域是在2020年3月。就在那时，市场的“担忧之墙”变得异常坚固，并能够支撑令人印象深刻的反弹。今天的那堵墙没有那么坚固了。</blockquote></p><p> The sentiment picture that the recent data are painting shows the market timers to be trigger-happy. They are quick to jump on the bullish bandwagon when the market rallies, and then jump on the bearish bandwagon when the market declines. As a result, both rallies and declines tend to be short-lived.</p><p><blockquote>最近的数据描绘的情绪图景显示，市场计时器乐于触发。当市场反弹时，他们会迅速加入看涨行列，然后当市场下跌时，他们会加入看跌行列。因此，无论是上涨还是下跌都往往是短暂的。</blockquote></p><p> A longer-lasting rally will require more extreme bearishness among the market timers, and for them to stubbornly hold onto their bearishness in the wake of the rally’s initial liftoff. Except for that to happen, the market to itself most likely would have to suffer a worse decline than we’ve experienced in recent days. In the meantime, enjoy this rally — while it lasts.</p><p><blockquote>更持久的反弹将需要市场计时器更加极端的看跌情绪，并且他们在反弹最初起飞后顽固地坚持看跌情绪。除非发生这种情况，否则市场本身很可能会遭受比我们最近几天经历的更严重的下跌。与此同时，享受这场反弹——趁它持续。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/why-any-stock-market-rally-right-now-will-be-quick-11620958836?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/why-any-stock-market-rally-right-now-will-be-quick-11620958836?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111018641","content_text":"Market-timers are running with the bulls but quick to turn bearish.\n\nContrarian investors suspect that the stock market’s recent decline has run its course — for now.\nThat’s because these market timers, especially those who focus on the NasdaqNDX,1.07%market in particular, have become sufficiently bearish that the short-term path of least resistance has turned up. Still, it’s not clear that any new rally will have much lasting power. An even more serious U.S. market decline cannot be ruled out over the coming couple of months.\nFor now, the recent decline appears to have been quite modest by historical standards, smaller even than what satisfies the semi-official definition of a correction as a 10% decline. Before Thursday’s big rally, the Dow Jones Industrial AverageDJIA,0.85%had fallen around 1,200 points from its previous all-time high, or 3.4%. The S&P 500SPX,0.98%was 4.0% below its high, and the Nasdaq CompositeCOMP,1.13%was down 7.8%.\nConsider how the Nasdaq-focused market timers reacted to these declines. As you can see from the chart below, their average recommended equity exposure (as represented by the Hulbert Nasdaq Newsletter Sentiment Index, or HNNSI) fell to minus 10.7%. That means that the Nasdaq-focused market timers are now recommending that their clients allocate an average of 10.7% of their equity trading portfolios to going short. As recently as April 29, this average exposure level stood at plus 83.6%.\n\nThat reflects a remarkably quick rush for the exits — 94.3 percentage points in just 10 trading sessions. In fact, out of the 5,000+ trading days since 2000, there have been only 18 — 0.3% — in which the HNNSI’s decline over the trailing 10 days was greater.\nTo appreciate the contrarian significance of this, consider that, on average following those past few occasions when the HNNSI declined by this much and this fast, the Nasdaq Composite was 5.3% higher in one month’s time.\nWhy, then, haven’t the contrarians become more bullish? The answer is also evident in the chart: The HNNSI’s plunge over the past 10 days stopped well short of the excessive bearish zone, defined as being in the bottom 10% of the historical distribution. That zone is represented by the beige-shaded box at the bottom of the chart.\nThe last time the HNNSI fell into that zone was in March 2020. That was when the market’s “wall of worry” became incredibly strong and was able to support an impressive rally. That wall today is not as strong.\nThe sentiment picture that the recent data are painting shows the market timers to be trigger-happy. They are quick to jump on the bullish bandwagon when the market rallies, and then jump on the bearish bandwagon when the market declines. As a result, both rallies and declines tend to be short-lived.\nA longer-lasting rally will require more extreme bearishness among the market timers, and for them to stubbornly hold onto their bearishness in the wake of the rally’s initial liftoff. Except for that to happen, the market to itself most likely would have to suffer a worse decline than we’ve experienced in recent days. In the meantime, enjoy this rally — while it lasts.","news_type":1,"symbols_score_info":{".DJI":0.9,".SPX":0.9,"SPY":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191070754,"gmtCreate":1620830434978,"gmtModify":1631885993771,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBUX\">$Starbucks(SBUX)$</a>dhisndf","listText":"<a href=\"https://laohu8.com/S/SBUX\">$Starbucks(SBUX)$</a>dhisndf","text":"$Starbucks(SBUX)$dhisndf","images":[{"img":"https://static.tigerbbs.com/727543736fc358cc12dc1929f8d98814","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/191070754","isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":191054560,"gmtCreate":1620829586050,"gmtModify":1631892033008,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"htmlText":"Uppppzz&nbsp;","listText":"Uppppzz&nbsp;","text":"Uppppzz","images":[{"img":"https://static.tigerbbs.com/49fdd8247005beda8b462ba7c63653b9","width":"1125","height":"2874"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/191054560","isVote":1,"tweetType":1,"viewCount":391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":134326282,"gmtCreate":1622209102946,"gmtModify":1631889244334,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/134326282","repostId":"2138107027","repostType":4,"isVote":1,"tweetType":1,"viewCount":3279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130340023,"gmtCreate":1621515459662,"gmtModify":1631892032985,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/130340023","repostId":"1125677133","repostType":4,"isVote":1,"tweetType":1,"viewCount":568,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":118594655,"gmtCreate":1622736920377,"gmtModify":1631889244270,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118594655","repostId":"2140247164","repostType":4,"isVote":1,"tweetType":1,"viewCount":1854,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":196929972,"gmtCreate":1621006367596,"gmtModify":1631892032996,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/196929972","repostId":"1111018641","repostType":4,"repost":{"id":"1111018641","kind":"news","pubTimestamp":1621000588,"share":"https://www.laohu8.com/m/news/1111018641?lang=zh_CN&edition=full","pubTime":"2021-05-14 21:56","market":"us","language":"en","title":"Opinion: Why any stock market rally right now will be quick<blockquote>观点：为什么现在股市反弹会很快</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111018641","media":"MarketWatch","summary":"Market-timers are running with the bulls but quick to turn bearish.\n\nContrarian investors suspect th","content":"<p>  <b>Market-timers are running with the bulls but quick to turn bearish.</b>  Contrarian investors suspect that the stock market’s recent decline has run its course — for now.</p><p><blockquote><b>市场定时器与多头一起运行，但很快就转向看跌。</b>逆向投资者怀疑股市最近的下跌已经结束——就目前而言。</blockquote></p><p> That’s because these market timers, especially those who focus on the NasdaqNDX,1.07%market in particular, have become sufficiently bearish that the short-term path of least resistance has turned up. Still, it’s not clear that any new rally will have much lasting power. An even more serious U.S. market decline cannot be ruled out over the coming couple of months.</p><p><blockquote>这是因为这些市场定时器，尤其是那些关注纳斯达克NDX（尤其是1.07%市场）的市场定时器，已经变得足够看跌，以至于阻力最小的短期路径已经出现。尽管如此，尚不清楚任何新的反弹是否会产生持久的力量。不排除未来几个月美国市场会出现更严重的下滑。</blockquote></p><p> For now, the recent decline appears to have been quite modest by historical standards, smaller even than what satisfies the semi-official definition of a correction as a 10% decline. Before Thursday’s big rally, the Dow Jones Industrial AverageDJIA,0.85%had fallen around 1,200 points from its previous all-time high, or 3.4%. The S&amp;P 500SPX,0.98%was 4.0% below its high, and the Nasdaq CompositeCOMP,1.13%was down 7.8%.</p><p><blockquote>就目前而言，按照历史标准，最近的跌幅似乎相当温和，甚至小于半官方定义的10%跌幅。在周四大幅上涨之前，道琼斯工业平均指数DJIA已较之前的历史高点（即3.4%）下跌约1,200点，跌幅为0.85%。标准普尔500SPX指数(0.98%)较高点低4.0%，纳斯达克综合指数(1.13%)下跌7.8%。</blockquote></p><p> Consider how the Nasdaq-focused market timers reacted to these declines. As you can see from the chart below, their average recommended equity exposure (as represented by the Hulbert Nasdaq Newsletter Sentiment Index, or HNNSI) fell to minus 10.7%. That means that the Nasdaq-focused market timers are now recommending that their clients allocate an average of 10.7% of their equity trading portfolios to going short. As recently as April 29, this average exposure level stood at plus 83.6%.</p><p><blockquote>考虑一下关注纳斯达克的市场定时器对这些下跌的反应。从下图可以看出，他们的平均推荐股票敞口（以赫伯特·纳斯达克时事通讯情绪指数（HNNSI）为代表）降至负10.7%。这意味着专注于纳斯达克的市场定时器现在建议他们的客户将平均10.7%的股票交易投资组合分配给做空。就在4月29日，这一平均暴露水平为+83.6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d550f647619d600d419397967f7bb778\" tg-width=\"1260\" tg-height=\"928\"></p><p><blockquote></blockquote></p><p> That reflects a remarkably quick rush for the exits — 94.3 percentage points in just 10 trading sessions. In fact, out of the 5,000+ trading days since 2000, there have been only 18 — 0.3% — in which the HNNSI’s decline over the trailing 10 days was greater.</p><p><blockquote>这反映出退出的速度非常快——短短10个交易日内就退出了94.3个百分点。事实上，自2000年以来的5,000多个交易日中，只有18-0.3%，其中HNNSI在过去10天的跌幅更大。</blockquote></p><p> To appreciate the contrarian significance of this, consider that, on average following those past few occasions when the HNNSI declined by this much and this fast, the Nasdaq Composite was 5.3% higher in one month’s time.</p><p><blockquote>为了理解这一点的逆向意义，请考虑一下，在过去几次HNNSI下跌幅度如此之大、如此之快之后，纳斯达克综合指数在一个月内平均上涨了5.3%。</blockquote></p><p> Why, then, haven’t the contrarians become more bullish? The answer is also evident in the chart: The HNNSI’s plunge over the past 10 days stopped well short of the excessive bearish zone, defined as being in the bottom 10% of the historical distribution. That zone is represented by the beige-shaded box at the bottom of the chart.</p><p><blockquote>那么，为什么逆向投资者没有变得更加看涨呢？答案在图表中也很明显：HNNSI在过去10天的暴跌远低于过度看跌区域，过度看跌区域被定义为处于历史分布的底部10%。该区域由图表底部的米色阴影框表示。</blockquote></p><p> The last time the HNNSI fell into that zone was in March 2020. That was when the market’s “wall of worry” became incredibly strong and was able to support an impressive rally. That wall today is not as strong.</p><p><blockquote>HNNSI上一次落入该区域是在2020年3月。就在那时，市场的“担忧之墙”变得异常坚固，并能够支撑令人印象深刻的反弹。今天的那堵墙没有那么坚固了。</blockquote></p><p> The sentiment picture that the recent data are painting shows the market timers to be trigger-happy. They are quick to jump on the bullish bandwagon when the market rallies, and then jump on the bearish bandwagon when the market declines. As a result, both rallies and declines tend to be short-lived.</p><p><blockquote>最近的数据描绘的情绪图景显示，市场计时器乐于触发。当市场反弹时，他们会迅速加入看涨行列，然后当市场下跌时，他们会加入看跌行列。因此，无论是上涨还是下跌都往往是短暂的。</blockquote></p><p> A longer-lasting rally will require more extreme bearishness among the market timers, and for them to stubbornly hold onto their bearishness in the wake of the rally’s initial liftoff. Except for that to happen, the market to itself most likely would have to suffer a worse decline than we’ve experienced in recent days. In the meantime, enjoy this rally — while it lasts.</p><p><blockquote>更持久的反弹将需要市场计时器更加极端的看跌情绪，并且他们在反弹最初起飞后顽固地坚持看跌情绪。除非发生这种情况，否则市场本身很可能会遭受比我们最近几天经历的更严重的下跌。与此同时，享受这场反弹——趁它持续。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opinion: Why any stock market rally right now will be quick<blockquote>观点：为什么现在股市反弹会很快</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpinion: Why any stock market rally right now will be quick<blockquote>观点：为什么现在股市反弹会很快</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-05-14 21:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>Market-timers are running with the bulls but quick to turn bearish.</b>  Contrarian investors suspect that the stock market’s recent decline has run its course — for now.</p><p><blockquote><b>市场定时器与多头一起运行，但很快就转向看跌。</b>逆向投资者怀疑股市最近的下跌已经结束——就目前而言。</blockquote></p><p> That’s because these market timers, especially those who focus on the NasdaqNDX,1.07%market in particular, have become sufficiently bearish that the short-term path of least resistance has turned up. Still, it’s not clear that any new rally will have much lasting power. An even more serious U.S. market decline cannot be ruled out over the coming couple of months.</p><p><blockquote>这是因为这些市场定时器，尤其是那些关注纳斯达克NDX（尤其是1.07%市场）的市场定时器，已经变得足够看跌，以至于阻力最小的短期路径已经出现。尽管如此，尚不清楚任何新的反弹是否会产生持久的力量。不排除未来几个月美国市场会出现更严重的下滑。</blockquote></p><p> For now, the recent decline appears to have been quite modest by historical standards, smaller even than what satisfies the semi-official definition of a correction as a 10% decline. Before Thursday’s big rally, the Dow Jones Industrial AverageDJIA,0.85%had fallen around 1,200 points from its previous all-time high, or 3.4%. The S&amp;P 500SPX,0.98%was 4.0% below its high, and the Nasdaq CompositeCOMP,1.13%was down 7.8%.</p><p><blockquote>就目前而言，按照历史标准，最近的跌幅似乎相当温和，甚至小于半官方定义的10%跌幅。在周四大幅上涨之前，道琼斯工业平均指数DJIA已较之前的历史高点（即3.4%）下跌约1,200点，跌幅为0.85%。标准普尔500SPX指数(0.98%)较高点低4.0%，纳斯达克综合指数(1.13%)下跌7.8%。</blockquote></p><p> Consider how the Nasdaq-focused market timers reacted to these declines. As you can see from the chart below, their average recommended equity exposure (as represented by the Hulbert Nasdaq Newsletter Sentiment Index, or HNNSI) fell to minus 10.7%. That means that the Nasdaq-focused market timers are now recommending that their clients allocate an average of 10.7% of their equity trading portfolios to going short. As recently as April 29, this average exposure level stood at plus 83.6%.</p><p><blockquote>考虑一下关注纳斯达克的市场定时器对这些下跌的反应。从下图可以看出，他们的平均推荐股票敞口（以赫伯特·纳斯达克时事通讯情绪指数（HNNSI）为代表）降至负10.7%。这意味着专注于纳斯达克的市场定时器现在建议他们的客户将平均10.7%的股票交易投资组合分配给做空。就在4月29日，这一平均暴露水平为+83.6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d550f647619d600d419397967f7bb778\" tg-width=\"1260\" tg-height=\"928\"></p><p><blockquote></blockquote></p><p> That reflects a remarkably quick rush for the exits — 94.3 percentage points in just 10 trading sessions. In fact, out of the 5,000+ trading days since 2000, there have been only 18 — 0.3% — in which the HNNSI’s decline over the trailing 10 days was greater.</p><p><blockquote>这反映出退出的速度非常快——短短10个交易日内就退出了94.3个百分点。事实上，自2000年以来的5,000多个交易日中，只有18-0.3%，其中HNNSI在过去10天的跌幅更大。</blockquote></p><p> To appreciate the contrarian significance of this, consider that, on average following those past few occasions when the HNNSI declined by this much and this fast, the Nasdaq Composite was 5.3% higher in one month’s time.</p><p><blockquote>为了理解这一点的逆向意义，请考虑一下，在过去几次HNNSI下跌幅度如此之大、如此之快之后，纳斯达克综合指数在一个月内平均上涨了5.3%。</blockquote></p><p> Why, then, haven’t the contrarians become more bullish? The answer is also evident in the chart: The HNNSI’s plunge over the past 10 days stopped well short of the excessive bearish zone, defined as being in the bottom 10% of the historical distribution. That zone is represented by the beige-shaded box at the bottom of the chart.</p><p><blockquote>那么，为什么逆向投资者没有变得更加看涨呢？答案在图表中也很明显：HNNSI在过去10天的暴跌远低于过度看跌区域，过度看跌区域被定义为处于历史分布的底部10%。该区域由图表底部的米色阴影框表示。</blockquote></p><p> The last time the HNNSI fell into that zone was in March 2020. That was when the market’s “wall of worry” became incredibly strong and was able to support an impressive rally. That wall today is not as strong.</p><p><blockquote>HNNSI上一次落入该区域是在2020年3月。就在那时，市场的“担忧之墙”变得异常坚固，并能够支撑令人印象深刻的反弹。今天的那堵墙没有那么坚固了。</blockquote></p><p> The sentiment picture that the recent data are painting shows the market timers to be trigger-happy. They are quick to jump on the bullish bandwagon when the market rallies, and then jump on the bearish bandwagon when the market declines. As a result, both rallies and declines tend to be short-lived.</p><p><blockquote>最近的数据描绘的情绪图景显示，市场计时器乐于触发。当市场反弹时，他们会迅速加入看涨行列，然后当市场下跌时，他们会加入看跌行列。因此，无论是上涨还是下跌都往往是短暂的。</blockquote></p><p> A longer-lasting rally will require more extreme bearishness among the market timers, and for them to stubbornly hold onto their bearishness in the wake of the rally’s initial liftoff. Except for that to happen, the market to itself most likely would have to suffer a worse decline than we’ve experienced in recent days. In the meantime, enjoy this rally — while it lasts.</p><p><blockquote>更持久的反弹将需要市场计时器更加极端的看跌情绪，并且他们在反弹最初起飞后顽固地坚持看跌情绪。除非发生这种情况，否则市场本身很可能会遭受比我们最近几天经历的更严重的下跌。与此同时，享受这场反弹——趁它持续。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/why-any-stock-market-rally-right-now-will-be-quick-11620958836?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/why-any-stock-market-rally-right-now-will-be-quick-11620958836?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111018641","content_text":"Market-timers are running with the bulls but quick to turn bearish.\n\nContrarian investors suspect that the stock market’s recent decline has run its course — for now.\nThat’s because these market timers, especially those who focus on the NasdaqNDX,1.07%market in particular, have become sufficiently bearish that the short-term path of least resistance has turned up. Still, it’s not clear that any new rally will have much lasting power. An even more serious U.S. market decline cannot be ruled out over the coming couple of months.\nFor now, the recent decline appears to have been quite modest by historical standards, smaller even than what satisfies the semi-official definition of a correction as a 10% decline. Before Thursday’s big rally, the Dow Jones Industrial AverageDJIA,0.85%had fallen around 1,200 points from its previous all-time high, or 3.4%. The S&P 500SPX,0.98%was 4.0% below its high, and the Nasdaq CompositeCOMP,1.13%was down 7.8%.\nConsider how the Nasdaq-focused market timers reacted to these declines. As you can see from the chart below, their average recommended equity exposure (as represented by the Hulbert Nasdaq Newsletter Sentiment Index, or HNNSI) fell to minus 10.7%. That means that the Nasdaq-focused market timers are now recommending that their clients allocate an average of 10.7% of their equity trading portfolios to going short. As recently as April 29, this average exposure level stood at plus 83.6%.\n\nThat reflects a remarkably quick rush for the exits — 94.3 percentage points in just 10 trading sessions. In fact, out of the 5,000+ trading days since 2000, there have been only 18 — 0.3% — in which the HNNSI’s decline over the trailing 10 days was greater.\nTo appreciate the contrarian significance of this, consider that, on average following those past few occasions when the HNNSI declined by this much and this fast, the Nasdaq Composite was 5.3% higher in one month’s time.\nWhy, then, haven’t the contrarians become more bullish? The answer is also evident in the chart: The HNNSI’s plunge over the past 10 days stopped well short of the excessive bearish zone, defined as being in the bottom 10% of the historical distribution. That zone is represented by the beige-shaded box at the bottom of the chart.\nThe last time the HNNSI fell into that zone was in March 2020. That was when the market’s “wall of worry” became incredibly strong and was able to support an impressive rally. That wall today is not as strong.\nThe sentiment picture that the recent data are painting shows the market timers to be trigger-happy. They are quick to jump on the bullish bandwagon when the market rallies, and then jump on the bearish bandwagon when the market declines. As a result, both rallies and declines tend to be short-lived.\nA longer-lasting rally will require more extreme bearishness among the market timers, and for them to stubbornly hold onto their bearishness in the wake of the rally’s initial liftoff. Except for that to happen, the market to itself most likely would have to suffer a worse decline than we’ve experienced in recent days. In the meantime, enjoy this rally — while it lasts.","news_type":1,"symbols_score_info":{".DJI":0.9,".SPX":0.9,"SPY":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119454643,"gmtCreate":1622560637282,"gmtModify":1631889244304,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119454643","repostId":"2140617694","repostType":4,"isVote":1,"tweetType":1,"viewCount":1950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142064787,"gmtCreate":1626104877449,"gmtModify":1631889244216,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142064787","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","kind":"news","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=zh_CN&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p><p><blockquote>（彭博社）-油价小幅走低，交易商正在努力应对几个地区新冠肺炎疫情死灰复燃和中国经济增长放缓对需求的影响。</blockquote></p><p> Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p><p><blockquote>纽约期货周一跌幅高达1.9%。日、韩、越部分地区为遏制德尔塔变异毒株疫情蔓延出台了新的流动限制措施，令石油需求前景蒙上阴影。与此同时，据报道，中国经济反弹放缓。美元走强也打压了价格，降低了以美元计价的大宗商品的吸引力。</blockquote></p><p> “As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p><p><blockquote>Again Capital LLC合伙人约翰·基尔达夫(John Kilduff)表示：“随着Covid-19变种继续严重打击亚洲，而亚洲确实是关键的摇摆需求中心，这对该综合体来说是一个非常非常大的负面影响。”</blockquote></p><p> Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p><p><blockquote>在全球供应紧张的情况下，美国和中国等经济体的燃料消耗今年提振了油价。OPEC及其盟友未能就增加供应达成一致，造成市场波动，并推动原油上周出现自5月以来的首次单周下跌。中国经济复苏放缓和德尔塔变异毒株蔓延可能威胁到全球石油需求和大宗商品今年迄今的走势。</blockquote></p><p> China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p><p><blockquote>根据彭博对经济学家的调查，中国第二季度的增长从第一季度创纪录的18.3%放缓至8%。零售销售和工业生产预计也将放缓。</blockquote></p><p> “There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p><p><blockquote>荷兰银行高级能源经济学家Hans van Cleef表示：“中国数据疲软，但欧洲德尔塔变异毒株的上升也引发了人们对需求复苏的一些怀疑。”</blockquote></p><p> The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p><p><blockquote>德尔塔变异毒株已经蔓延到世界各地，包括自5月中旬以来报告病例最多的美国。在欧洲，英国和法国官员正在就新病例和重新开放发出警告。</blockquote></p><p> Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p><p><blockquote>欧佩克+即将供应的不确定性继续笼罩着市场。在成员国之间就减产发生争执后，该联盟上周放弃了会议，一周后，仍未达成协议。</blockquote></p><p> “They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p><p><blockquote>Again Capital LLC的基尔达夫表示：“他们将在一定程度上提高，这只是幅度以及是否会崩溃的问题。”</blockquote></p><p> The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p><p><blockquote>国际能源署将于周二发布月度报告，为投资者提供市场概况，而OPEC将于周四发布自己的月度报告。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-07-12 23:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p><p><blockquote>（彭博社）-油价小幅走低，交易商正在努力应对几个地区新冠肺炎疫情死灰复燃和中国经济增长放缓对需求的影响。</blockquote></p><p> Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p><p><blockquote>纽约期货周一跌幅高达1.9%。日、韩、越部分地区为遏制德尔塔变异毒株疫情蔓延出台了新的流动限制措施，令石油需求前景蒙上阴影。与此同时，据报道，中国经济反弹放缓。美元走强也打压了价格，降低了以美元计价的大宗商品的吸引力。</blockquote></p><p> “As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p><p><blockquote>Again Capital LLC合伙人约翰·基尔达夫(John Kilduff)表示：“随着Covid-19变种继续严重打击亚洲，而亚洲确实是关键的摇摆需求中心，这对该综合体来说是一个非常非常大的负面影响。”</blockquote></p><p> Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p><p><blockquote>在全球供应紧张的情况下，美国和中国等经济体的燃料消耗今年提振了油价。OPEC及其盟友未能就增加供应达成一致，造成市场波动，并推动原油上周出现自5月以来的首次单周下跌。中国经济复苏放缓和德尔塔变异毒株蔓延可能威胁到全球石油需求和大宗商品今年迄今的走势。</blockquote></p><p> China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p><p><blockquote>根据彭博对经济学家的调查，中国第二季度的增长从第一季度创纪录的18.3%放缓至8%。零售销售和工业生产预计也将放缓。</blockquote></p><p> “There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p><p><blockquote>荷兰银行高级能源经济学家Hans van Cleef表示：“中国数据疲软，但欧洲德尔塔变异毒株的上升也引发了人们对需求复苏的一些怀疑。”</blockquote></p><p> The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p><p><blockquote>德尔塔变异毒株已经蔓延到世界各地，包括自5月中旬以来报告病例最多的美国。在欧洲，英国和法国官员正在就新病例和重新开放发出警告。</blockquote></p><p> Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p><p><blockquote>欧佩克+即将供应的不确定性继续笼罩着市场。在成员国之间就减产发生争执后，该联盟上周放弃了会议，一周后，仍未达成协议。</blockquote></p><p> “They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p><p><blockquote>Again Capital LLC的基尔达夫表示：“他们将在一定程度上提高，这只是幅度以及是否会崩溃的问题。”</blockquote></p><p> The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p><p><blockquote>国际能源署将于周二发布月度报告，为投资者提供市场概况，而OPEC将于周四发布自己的月度报告。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1,"symbols_score_info":{"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114481303,"gmtCreate":1623087740802,"gmtModify":1631889244259,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/114481303","repostId":"1133110564","repostType":4,"repost":{"id":"1133110564","kind":"news","pubTimestamp":1623080895,"share":"https://www.laohu8.com/m/news/1133110564?lang=zh_CN&edition=full","pubTime":"2021-06-07 23:48","market":"us","language":"en","title":"Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健(Biogen)阿尔茨海默病药物获得FDA批准</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133110564","media":"zerohedge","summary":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's ","content":"<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p><p><blockquote>FDA周一批准了Biogen用于治疗阿尔茨海默氏症生理原因的实验药物Aduhelm（aducanumab），作为第一种解决该疾病潜在原因的治疗方法，尽管该药物的临床试验结果明显好坏参半。</blockquote></p><p> AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p><p><blockquote>正如路透社解释的那样，Aduhelm是一长串药物之一，这些药物旨在清除早期阿尔茨海默氏症患者大脑中一种称为β淀粉样蛋白的蛋白质的粘性沉积物，以避免这种疾病最严重的破坏，这种疾病的特点是严重的记忆丧失和生活自理能力的丧失。</blockquote></p><p> The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p><p><blockquote>Aduhelm的临床试验首次表明，这些斑块（被认为是该疾病的标志性症状）的减少可以减缓患者的临床衰退。</blockquote></p><p> The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p><p><blockquote>FDA的新闻稿中提到，该药物在专业界造成了裂痕：该机构表示，Biogen提交的数据（来自两项3期临床试验）“非常复杂，在临床益处方面留下了残余的不确定性。关于Aduhelm是否应该被批准，公众存在相当大的争论。正如在解释科学数据时经常出现的情况一样，专家群体提供了不同的观点。”许多科学家反对该药物的批准，称其不起作用。</blockquote></p><p> As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p><p><blockquote>因此，Biogen将被要求进行另一轮批准后临床研究（FDA称之为“4期”试验）。</blockquote></p><p> Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p><p><blockquote>Biogen的新药是自2003年以来首个获批的阿尔茨海默病治疗药物。该疾病的现有治疗课程并没有多大作用来阻止潜在的原因，而是旨在让患者更舒适。</blockquote></p><p> FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p><p><blockquote>FDA批准Aduhelm使用加速批准途径治疗阿尔茨海默病患者，由于该药物在减少β淀粉样蛋白脑斑块方面取得了成功，因此获得了批准。</blockquote></p><p> Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p><p><blockquote>消息传出后，百健(Biogen)的股价上涨，其他已知致力于阿尔茨海默氏症治疗的公司的股价也上涨，其中包括百健(Biogen)的竞争对手礼来公司(Eli Lilly)。纳斯达克生物科技指数攀升至盘中高点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p><p><blockquote><u><b>阅读下面的完整新闻稿：</b></u></blockquote></p><p> <i>Today FDA approved&nbsp;Aduhelm (aducanumab)&nbsp;to treat patients with Alzheimer’s disease using the&nbsp;Accelerated Approval&nbsp;pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p><p><blockquote><i>今天，FDA批准Aduhelm（aducanumab）使用加速批准途径治疗阿尔茨海默病患者，根据该途径，FDA批准一种治疗严重或危及生命疾病的药物，当该药物被证明对替代终点有影响时，该药物可能比现有治疗提供有意义的治疗益处，该终点有合理的可能性预测患者的临床益处，并且该药物的临床益处仍存在一些不确定性。</i></blockquote></p><p> <i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.&nbsp; The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p><p><blockquote><i>这一批准在许多方面都意义重大。Aduhelm是自2003年以来首个被批准用于治疗阿尔茨海默病的新型疗法。也许更重要的是，Aduhelm是第一个针对阿尔茨海默病潜在病理生理学的治疗方法，即大脑中淀粉样β斑块的存在。Aduhelm的临床试验首次表明，这些斑块的减少——这是阿尔茨海默病患者大脑中的标志性发现——有望导致这种毁灭性痴呆症的临床下降减少。</i></blockquote></p><p> <i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p><p><blockquote><i>我们很清楚围绕这一批准的关注。我们知道Aduhelm已经引起了媒体、阿尔茨海默氏症患者群体、我们当选的官员和其他感兴趣的利益相关者的关注。随着一种严重的、危及生命的疾病的治疗悬而未决，这么多人关注这次审查的结果是有道理的。此外，申请人提交的数据非常复杂，并留下了关于临床获益的剩余不确定性。关于Aduhelm是否应该获得批准，公众进行了大量辩论。正如解释科学数据时经常出现的情况一样，专家群体提供了不同的观点。</i></blockquote></p><p></p><p> <i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the&nbsp;Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p><p><blockquote><i>归根结底，在数据不直观的情况下做出监管决策时，我们遵循了通常的行动方针。我们仔细检查了临床试验结果，征求了外周和中枢神经系统药物咨询委员会的意见，听取了患者群体的观点，并审查了所有相关数据。我们最终决定使用加速批准途径——该途径旨在为患有严重疾病的患者提供更早获得潜在有价值的治疗，这些患者的需求未得到满足，并且尽管该益处仍存在一些剩余的不确定性，但仍有望获得临床益处。在确定该申请符合加速批准的要求时，该机构得出结论，Aduhelm对阿尔茨海默病患者的益处超过了该疗法的风险。</i></blockquote></p><p> <i><b>What the Data Show</b></i></p><p><blockquote><i><b>数据显示了什么</b></i></blockquote></p><p> <i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. &nbsp;In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. &nbsp;It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p><p><blockquote><i>Aduhelm的后期开发计划包括两项3期临床试验。一项研究达到了主要终点，显示临床下降减少。第二项试验未达到主要终点。然而，在所有对其进行评估的研究中，Aduhelm以剂量和时间依赖性方式持续且非常令人信服地降低了大脑中淀粉样蛋白斑块的水平。预计淀粉样斑块的减少将导致临床下降的减少。</i></blockquote></p><p> <i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p><p><blockquote><i>我们知道，于2020年11月召开会议审查临床试验数据并讨论支持Aduhelm申请的证据的外周和中枢神经系统药物咨询委员会并不同意将one成功试验的临床获益视为支持批准的主要证据是合理的。咨询委员会没有讨论加速核准的备选办法。如上所述，在所有试验中都清楚地表明，用Aduhelm治疗可显著减少β淀粉样蛋白斑块。斑块的这种减少很可能导致临床益处。在咨询委员会提供反馈后，我们继续进行审查和审议，我们决定Aduhelm申请中提出的证据符合加速批准的标准。我们感谢咨询委员会对数据的独立审查和宝贵意见。</i></blockquote></p><p> <i><b>Accelerated Approval</b></i></p><p><blockquote><i><b>加速审批</b></i></blockquote></p><p> <i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.&nbsp; Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).&nbsp; A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p><p><blockquote><i>FDA制定了加速批准计划，以允许更早批准治疗严重疾病和满足未满足的医疗需求的药物。批准基于替代或中间临床终点（在这种情况下，大脑中淀粉样斑块的减少）。替代终点是一种标记，如实验室测量、射线照相图像、体征或其他被认为预测临床益处但其本身不是临床益处的测量。替代终点的使用可以大大缩短获得FDA批准之前所需的时间。</i></blockquote></p><p> <i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p><p><blockquote><i>制药公司需要进行批准后研究，以验证预期的临床益处。这些研究被称为4期验证性试验。如果验证性试验未能验证该药物的预期临床益处，FDA已制定监管程序，可能会导致该药物退出市场。</i></blockquote></p><p> <i><b>The Devastation of Alzheimer’s Disease</b></i></p><p><blockquote><i><b>阿尔茨海默病的破坏</b></i></blockquote></p><p> <i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p><p><blockquote><i>综上所述，我们非常清楚阿尔茨海默病造成的逐渐和累积的破坏，因为随着时间的推移，患者会失去记忆和认知功能。在晚期疾病中，人们不再能够进行对话或对环境做出反应。平均而言，阿尔茨海默病患者在诊断后可以活4到8年，但有些患者可以活20年。</i></blockquote></p><p> <i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p><p><blockquote><i>治疗的需求是迫切的：目前，超过600万美国人患有阿尔茨海默病，随着人口老龄化，这一数字预计还会增加。阿尔茨海默氏症是美国第六大死亡原因。</i></blockquote></p><p> <i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. &nbsp;As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p><p><blockquote><i>尽管Aduhelm的临床益处数据很复杂，但FDA已经确定，有大量证据表明Aduhelm减少了大脑中的β淀粉样蛋白斑块，并且这些斑块的减少很可能预示着对患者的重要益处。由于FDA批准Aduhelm，阿尔茨海默病患者有了一种重要而关键的新疗法，可以帮助对抗这种疾病。</i></blockquote></p><p></p><p> <i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p><p><blockquote><i>FDA将继续监测Aduhelm进入市场并最终到达患者床边的情况。此外，FDA要求Biogen进行批准后临床试验，以验证该药物的临床益处。如果药物没有按预期发挥作用，我们可以采取措施将其从市场上撤下。但希望随着越来越多的人接受Aduhelm，我们将在临床试验中看到进一步的益处证据。作为一个机构，我们还将继续致力于促进这种灾难性疾病的药物开发。</i></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健(Biogen)阿尔茨海默病药物获得FDA批准</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nControversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健(Biogen)阿尔茨海默病药物获得FDA批准</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">zerohedge</strong><span class=\"h-time small\">2021-06-07 23:48</span>\n</p>\n</h4>\n</header>\n<article>\n<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p><p><blockquote>FDA周一批准了Biogen用于治疗阿尔茨海默氏症生理原因的实验药物Aduhelm（aducanumab），作为第一种解决该疾病潜在原因的治疗方法，尽管该药物的临床试验结果明显好坏参半。</blockquote></p><p> AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p><p><blockquote>正如路透社解释的那样，Aduhelm是一长串药物之一，这些药物旨在清除早期阿尔茨海默氏症患者大脑中一种称为β淀粉样蛋白的蛋白质的粘性沉积物，以避免这种疾病最严重的破坏，这种疾病的特点是严重的记忆丧失和生活自理能力的丧失。</blockquote></p><p> The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p><p><blockquote>Aduhelm的临床试验首次表明，这些斑块（被认为是该疾病的标志性症状）的减少可以减缓患者的临床衰退。</blockquote></p><p> The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p><p><blockquote>FDA的新闻稿中提到，该药物在专业界造成了裂痕：该机构表示，Biogen提交的数据（来自两项3期临床试验）“非常复杂，在临床益处方面留下了残余的不确定性。关于Aduhelm是否应该被批准，公众存在相当大的争论。正如在解释科学数据时经常出现的情况一样，专家群体提供了不同的观点。”许多科学家反对该药物的批准，称其不起作用。</blockquote></p><p> As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p><p><blockquote>因此，Biogen将被要求进行另一轮批准后临床研究（FDA称之为“4期”试验）。</blockquote></p><p> Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p><p><blockquote>Biogen的新药是自2003年以来首个获批的阿尔茨海默病治疗药物。该疾病的现有治疗课程并没有多大作用来阻止潜在的原因，而是旨在让患者更舒适。</blockquote></p><p> FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p><p><blockquote>FDA批准Aduhelm使用加速批准途径治疗阿尔茨海默病患者，由于该药物在减少β淀粉样蛋白脑斑块方面取得了成功，因此获得了批准。</blockquote></p><p> Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p><p><blockquote>消息传出后，百健(Biogen)的股价上涨，其他已知致力于阿尔茨海默氏症治疗的公司的股价也上涨，其中包括百健(Biogen)的竞争对手礼来公司(Eli Lilly)。纳斯达克生物科技指数攀升至盘中高点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p><p><blockquote><u><b>阅读下面的完整新闻稿：</b></u></blockquote></p><p> <i>Today FDA approved&nbsp;Aduhelm (aducanumab)&nbsp;to treat patients with Alzheimer’s disease using the&nbsp;Accelerated Approval&nbsp;pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p><p><blockquote><i>今天，FDA批准Aduhelm（aducanumab）使用加速批准途径治疗阿尔茨海默病患者，根据该途径，FDA批准一种治疗严重或危及生命疾病的药物，当该药物被证明对替代终点有影响时，该药物可能比现有治疗提供有意义的治疗益处，该终点有合理的可能性预测患者的临床益处，并且该药物的临床益处仍存在一些不确定性。</i></blockquote></p><p> <i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.&nbsp; The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p><p><blockquote><i>这一批准在许多方面都意义重大。Aduhelm是自2003年以来首个被批准用于治疗阿尔茨海默病的新型疗法。也许更重要的是，Aduhelm是第一个针对阿尔茨海默病潜在病理生理学的治疗方法，即大脑中淀粉样β斑块的存在。Aduhelm的临床试验首次表明，这些斑块的减少——这是阿尔茨海默病患者大脑中的标志性发现——有望导致这种毁灭性痴呆症的临床下降减少。</i></blockquote></p><p> <i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p><p><blockquote><i>我们很清楚围绕这一批准的关注。我们知道Aduhelm已经引起了媒体、阿尔茨海默氏症患者群体、我们当选的官员和其他感兴趣的利益相关者的关注。随着一种严重的、危及生命的疾病的治疗悬而未决，这么多人关注这次审查的结果是有道理的。此外，申请人提交的数据非常复杂，并留下了关于临床获益的剩余不确定性。关于Aduhelm是否应该获得批准，公众进行了大量辩论。正如解释科学数据时经常出现的情况一样，专家群体提供了不同的观点。</i></blockquote></p><p></p><p> <i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the&nbsp;Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p><p><blockquote><i>归根结底，在数据不直观的情况下做出监管决策时，我们遵循了通常的行动方针。我们仔细检查了临床试验结果，征求了外周和中枢神经系统药物咨询委员会的意见，听取了患者群体的观点，并审查了所有相关数据。我们最终决定使用加速批准途径——该途径旨在为患有严重疾病的患者提供更早获得潜在有价值的治疗，这些患者的需求未得到满足，并且尽管该益处仍存在一些剩余的不确定性，但仍有望获得临床益处。在确定该申请符合加速批准的要求时，该机构得出结论，Aduhelm对阿尔茨海默病患者的益处超过了该疗法的风险。</i></blockquote></p><p> <i><b>What the Data Show</b></i></p><p><blockquote><i><b>数据显示了什么</b></i></blockquote></p><p> <i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. &nbsp;In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. &nbsp;It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p><p><blockquote><i>Aduhelm的后期开发计划包括两项3期临床试验。一项研究达到了主要终点，显示临床下降减少。第二项试验未达到主要终点。然而，在所有对其进行评估的研究中，Aduhelm以剂量和时间依赖性方式持续且非常令人信服地降低了大脑中淀粉样蛋白斑块的水平。预计淀粉样斑块的减少将导致临床下降的减少。</i></blockquote></p><p> <i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p><p><blockquote><i>我们知道，于2020年11月召开会议审查临床试验数据并讨论支持Aduhelm申请的证据的外周和中枢神经系统药物咨询委员会并不同意将one成功试验的临床获益视为支持批准的主要证据是合理的。咨询委员会没有讨论加速核准的备选办法。如上所述，在所有试验中都清楚地表明，用Aduhelm治疗可显著减少β淀粉样蛋白斑块。斑块的这种减少很可能导致临床益处。在咨询委员会提供反馈后，我们继续进行审查和审议，我们决定Aduhelm申请中提出的证据符合加速批准的标准。我们感谢咨询委员会对数据的独立审查和宝贵意见。</i></blockquote></p><p> <i><b>Accelerated Approval</b></i></p><p><blockquote><i><b>加速审批</b></i></blockquote></p><p> <i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.&nbsp; Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).&nbsp; A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p><p><blockquote><i>FDA制定了加速批准计划，以允许更早批准治疗严重疾病和满足未满足的医疗需求的药物。批准基于替代或中间临床终点（在这种情况下，大脑中淀粉样斑块的减少）。替代终点是一种标记，如实验室测量、射线照相图像、体征或其他被认为预测临床益处但其本身不是临床益处的测量。替代终点的使用可以大大缩短获得FDA批准之前所需的时间。</i></blockquote></p><p> <i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p><p><blockquote><i>制药公司需要进行批准后研究，以验证预期的临床益处。这些研究被称为4期验证性试验。如果验证性试验未能验证该药物的预期临床益处，FDA已制定监管程序，可能会导致该药物退出市场。</i></blockquote></p><p> <i><b>The Devastation of Alzheimer’s Disease</b></i></p><p><blockquote><i><b>阿尔茨海默病的破坏</b></i></blockquote></p><p> <i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p><p><blockquote><i>综上所述，我们非常清楚阿尔茨海默病造成的逐渐和累积的破坏，因为随着时间的推移，患者会失去记忆和认知功能。在晚期疾病中，人们不再能够进行对话或对环境做出反应。平均而言，阿尔茨海默病患者在诊断后可以活4到8年，但有些患者可以活20年。</i></blockquote></p><p> <i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p><p><blockquote><i>治疗的需求是迫切的：目前，超过600万美国人患有阿尔茨海默病，随着人口老龄化，这一数字预计还会增加。阿尔茨海默氏症是美国第六大死亡原因。</i></blockquote></p><p> <i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. &nbsp;As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p><p><blockquote><i>尽管Aduhelm的临床益处数据很复杂，但FDA已经确定，有大量证据表明Aduhelm减少了大脑中的β淀粉样蛋白斑块，并且这些斑块的减少很可能预示着对患者的重要益处。由于FDA批准Aduhelm，阿尔茨海默病患者有了一种重要而关键的新疗法，可以帮助对抗这种疾病。</i></blockquote></p><p></p><p> <i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p><p><blockquote><i>FDA将继续监测Aduhelm进入市场并最终到达患者床边的情况。此外，FDA要求Biogen进行批准后临床试验，以验证该药物的临床益处。如果药物没有按预期发挥作用，我们可以采取措施将其从市场上撤下。但希望随着越来越多的人接受Aduhelm，我们将在临床试验中看到进一步的益处证据。作为一个机构，我们还将继续致力于促进这种灾难性疾病的药物开发。</i></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">zerohedge</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133110564","content_text":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.\nAsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.\nThe clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.\nThe drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.\nAs a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).\nBiogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.\nFDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.\nShares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.\nRead the full press release below:\nToday FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.\nThis approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.  The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.\nWe are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\nAt the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.\nWhat the Data Show\nThe late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint.  In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion.  It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.\nWe know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.\nAccelerated Approval\nThe FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.  Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain).  A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.\nDrug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.\nThe Devastation of Alzheimer’s Disease\nWith all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.\nThe need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.\nAlthough the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients.  As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.\nFDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":2487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":192373380,"gmtCreate":1621153405640,"gmtModify":1631892032993,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/192373380","repostId":"1163454382","repostType":4,"repost":{"id":"1163454382","kind":"news","pubTimestamp":1621004581,"share":"https://www.laohu8.com/m/news/1163454382?lang=zh_CN&edition=full","pubTime":"2021-05-14 23:03","market":"us","language":"en","title":"Why AMC Entertainment Stock Jumped Again Friday<blockquote>为什么AMC院线股价周五再次上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163454382","media":"Motley Fool","summary":"AMC investors have reason for more optimism on the heels of another capital raise.Yesterday's jump came after the company announcedit raised $428 million. First, the Centers for Disease Control and Prevention  issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.This should allow theaters to open back up at full capacity and be a desirable destination for vaccinat","content":"<p>  <b>AMC investors have reason for more optimism on the heels of another capital raise.</b>  <b>What happened</b></p><p><blockquote><b>在再次融资后，AMC投资者有理由更加乐观。</b><b>发生了什么</b></blockquote></p><p> A day after<b>AMC Entertainment Holdings</b>(NYSE:AMC)</p><p><blockquote>一天后<b>AMC院线控股</b>（纽约证券交易所代码：AMC）</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Yesterday's jump came after the company announcedit raised $428 million</p><p><blockquote>昨天的股价上涨是在该公司宣布筹集4.28亿美元后发生的</blockquote></p><p> First, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.</p><p><blockquote>首先，美国疾病控制和预防中心（CDC）发布了一份关于当前健康和安全协议的新声明，称完全接种疫苗的人可以在不戴口罩或保持身体距离的情况下恢复活动，包括在室内。</blockquote></p><p> This should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,<b>Walt Disney</b>(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.</p><p><blockquote>这将使电影院能够满负荷开放，并成为接种疫苗的电影顾客的理想目的地。同样在昨天，<b>迪斯尼</b>（纽约证券交易所股票代码：DIS）宣布了季度收益报告，首席执行官鲍勃·查佩克指出“我们工作室的产量有所增加”。虽然这对影院运营商来说是积极的，但迪士尼也报告称其流媒体服务的用户增长令人失望。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Lower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.</p><p><blockquote>流媒体订阅量的下降对影院业务来说可能是一个积极的信号。随着疫苗接种的继续推广，以及疾病预防控制中心现在正式批准在不戴口罩的情况下与人群聚集在室内，剧院的上座率可能会很快恢复。</blockquote></p><p> Vaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.</p><p><blockquote>疫苗接种将促使人们回到户外活动。在一年多的时间里，电影院可能会成为人们最喜欢的目的地。在另一次融资之后，AMC投资者可能认为这家公司终于有了一条充满希望的未来之路。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMC Entertainment Stock Jumped Again Friday<blockquote>为什么AMC院线股价周五再次上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMC Entertainment Stock Jumped Again Friday<blockquote>为什么AMC院线股价周五再次上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-05-14 23:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>AMC investors have reason for more optimism on the heels of another capital raise.</b>  <b>What happened</b></p><p><blockquote><b>在再次融资后，AMC投资者有理由更加乐观。</b><b>发生了什么</b></blockquote></p><p> A day after<b>AMC Entertainment Holdings</b>(NYSE:AMC)</p><p><blockquote>一天后<b>AMC院线控股</b>（纽约证券交易所代码：AMC）</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Yesterday's jump came after the company announcedit raised $428 million</p><p><blockquote>昨天的股价上涨是在该公司宣布筹集4.28亿美元后发生的</blockquote></p><p> First, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.</p><p><blockquote>首先，美国疾病控制和预防中心（CDC）发布了一份关于当前健康和安全协议的新声明，称完全接种疫苗的人可以在不戴口罩或保持身体距离的情况下恢复活动，包括在室内。</blockquote></p><p> This should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,<b>Walt Disney</b>(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.</p><p><blockquote>这将使电影院能够满负荷开放，并成为接种疫苗的电影顾客的理想目的地。同样在昨天，<b>迪斯尼</b>（纽约证券交易所股票代码：DIS）宣布了季度收益报告，首席执行官鲍勃·查佩克指出“我们工作室的产量有所增加”。虽然这对影院运营商来说是积极的，但迪士尼也报告称其流媒体服务的用户增长令人失望。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Lower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.</p><p><blockquote>流媒体订阅量的下降对影院业务来说可能是一个积极的信号。随着疫苗接种的继续推广，以及疾病预防控制中心现在正式批准在不戴口罩的情况下与人群聚集在室内，剧院的上座率可能会很快恢复。</blockquote></p><p> Vaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.</p><p><blockquote>疫苗接种将促使人们回到户外活动。在一年多的时间里，电影院可能会成为人们最喜欢的目的地。在另一次融资之后，AMC投资者可能认为这家公司终于有了一条充满希望的未来之路。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/05/14/why-amc-entertainment-stock-jumped-again-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163454382","content_text":"AMC investors have reason for more optimism on the heels of another capital raise.\n\nWhat happened\nA day afterAMC Entertainment Holdings(NYSE:AMC)\nSo what\nYesterday's jump came after the company announcedit raised $428 million\nFirst, the Centers for Disease Control and Prevention (CDC) issued a new statement on current health and safety protocols saying that fully vaccinated people can resume activities without wearing a mask or physically distancing, including indoors.\nThis should allow theaters to open back up at full capacity and be a desirable destination for vaccinated movie patrons. Also yesterday,Walt Disney(NYSE:DIS)announced its quarterly earnings report, and CEO Bob Chapek noted \"increased production at our studios.\" While that is a positive for theater operators, Disney also reported disappointing subscriber growth in itsstreaming services.\nNow what\nLower streaming subscriptions could be a positive sign for the theater business. As vaccinations continue to roll out, and with the CDC now officially giving its approval to gather indoors with crowds and without masks, theater attendance may resume quickly.\nVaccinations are going to drive people back to activities outside the home. Movie theaters are likely to be a favorite destination after more than a year of mostly watching at home. On the heels of another capital raise, AMC investors may be thinking this company finally has a promising path ahead.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142067113,"gmtCreate":1626104891732,"gmtModify":1631889244205,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142067113","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","kind":"news","pubTimestamp":1626102184,"share":"https://www.laohu8.com/m/news/1143990601?lang=zh_CN&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p><p><blockquote>（彭博社）-油价小幅走低，交易商正在努力应对几个地区新冠肺炎疫情死灰复燃和中国经济增长放缓对需求的影响。</blockquote></p><p> Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p><p><blockquote>纽约期货周一跌幅高达1.9%。日、韩、越部分地区为遏制德尔塔变异毒株疫情蔓延出台了新的流动限制措施，令石油需求前景蒙上阴影。与此同时，据报道，中国经济反弹放缓。美元走强也打压了价格，降低了以美元计价的大宗商品的吸引力。</blockquote></p><p> “As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p><p><blockquote>Again Capital LLC合伙人约翰·基尔达夫(John Kilduff)表示：“随着Covid-19变种继续严重打击亚洲，而亚洲确实是关键的摇摆需求中心，这对该综合体来说是一个非常非常大的负面影响。”</blockquote></p><p> Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p><p><blockquote>在全球供应紧张的情况下，美国和中国等经济体的燃料消耗今年提振了油价。OPEC及其盟友未能就增加供应达成一致，造成市场波动，并推动原油上周出现自5月以来的首次单周下跌。中国经济复苏放缓和德尔塔变异毒株蔓延可能威胁到全球石油需求和大宗商品今年迄今的走势。</blockquote></p><p> China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p><p><blockquote>根据彭博对经济学家的调查，中国第二季度的增长从第一季度创纪录的18.3%放缓至8%。零售销售和工业生产预计也将放缓。</blockquote></p><p> “There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p><p><blockquote>荷兰银行高级能源经济学家Hans van Cleef表示：“中国数据疲软，但欧洲德尔塔变异毒株的上升也引发了人们对需求复苏的一些怀疑。”</blockquote></p><p> The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p><p><blockquote>德尔塔变异毒株已经蔓延到世界各地，包括自5月中旬以来报告病例最多的美国。在欧洲，英国和法国官员正在就新病例和重新开放发出警告。</blockquote></p><p> Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p><p><blockquote>欧佩克+即将供应的不确定性继续笼罩着市场。在成员国之间就减产发生争执后，该联盟上周放弃了会议，一周后，仍未达成协议。</blockquote></p><p> “They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p><p><blockquote>Again Capital LLC的基尔达夫表示：“他们将在一定程度上提高，这只是幅度以及是否会崩溃的问题。”</blockquote></p><p> The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p><p><blockquote>国际能源署将于周二发布月度报告，为投资者提供市场概况，而OPEC将于周四发布自己的月度报告。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁日益严重，油价下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-07-12 23:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.</p><p><blockquote>（彭博社）-油价小幅走低，交易商正在努力应对几个地区新冠肺炎疫情死灰复燃和中国经济增长放缓对需求的影响。</blockquote></p><p> Futures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.</p><p><blockquote>纽约期货周一跌幅高达1.9%。日、韩、越部分地区为遏制德尔塔变异毒株疫情蔓延出台了新的流动限制措施，令石油需求前景蒙上阴影。与此同时，据报道，中国经济反弹放缓。美元走强也打压了价格，降低了以美元计价的大宗商品的吸引力。</blockquote></p><p> “As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.</p><p><blockquote>Again Capital LLC合伙人约翰·基尔达夫(John Kilduff)表示：“随着Covid-19变种继续严重打击亚洲，而亚洲确实是关键的摇摆需求中心，这对该综合体来说是一个非常非常大的负面影响。”</blockquote></p><p> Fuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.</p><p><blockquote>在全球供应紧张的情况下，美国和中国等经济体的燃料消耗今年提振了油价。OPEC及其盟友未能就增加供应达成一致，造成市场波动，并推动原油上周出现自5月以来的首次单周下跌。中国经济复苏放缓和德尔塔变异毒株蔓延可能威胁到全球石油需求和大宗商品今年迄今的走势。</blockquote></p><p> China’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.</p><p><blockquote>根据彭博对经济学家的调查，中国第二季度的增长从第一季度创纪录的18.3%放缓至8%。零售销售和工业生产预计也将放缓。</blockquote></p><p> “There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.</p><p><blockquote>荷兰银行高级能源经济学家Hans van Cleef表示：“中国数据疲软，但欧洲德尔塔变异毒株的上升也引发了人们对需求复苏的一些怀疑。”</blockquote></p><p> The delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.</p><p><blockquote>德尔塔变异毒株已经蔓延到世界各地，包括自5月中旬以来报告病例最多的美国。在欧洲，英国和法国官员正在就新病例和重新开放发出警告。</blockquote></p><p> Uncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.</p><p><blockquote>欧佩克+即将供应的不确定性继续笼罩着市场。在成员国之间就减产发生争执后，该联盟上周放弃了会议，一周后，仍未达成协议。</blockquote></p><p> “They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.</p><p><blockquote>Again Capital LLC的基尔达夫表示：“他们将在一定程度上提高，这只是幅度以及是否会崩溃的问题。”</blockquote></p><p> The International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.</p><p><blockquote>国际能源署将于周二发布月度报告，为投资者提供市场概况，而OPEC将于周四发布自己的月度报告。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1,"symbols_score_info":{"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119455704,"gmtCreate":1622560602508,"gmtModify":1631889244319,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":"Weeee","listText":"Weeee","text":"Weeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119455704","repostId":"2138889344","repostType":4,"repost":{"id":"2138889344","kind":"news","pubTimestamp":1622546894,"share":"https://www.laohu8.com/m/news/2138889344?lang=zh_CN&edition=full","pubTime":"2021-06-01 19:28","market":"us","language":"en","title":"Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将报告第一季度收益：前景如何？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2138889344","media":"Zacks","summary":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarte","content":"<p><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</b> is set to report first-quarter fiscal 2022 results on Jun 1.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a>视频通信</b>定于6月1日公布2022财年第一季度业绩。</blockquote></p><p>For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.</p><p><blockquote>该公司预计本季度非GAAP每股收益在95美分至97美分之间。总收入预计在9亿美元至9.05亿美元之间。</blockquote></p><p>The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.</p><p><blockquote>过去30天，Zacks对收益的一致预期保持在每股97美分。该公司报告去年同期每股收益为20美分。</blockquote></p><p>The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.</p><p><blockquote>收入的共识为9.052亿美元，比去年同期报告的数字增长175.8%。</blockquote></p><p><h3>Zoom Video Communications, Inc. Price and EPS Surprise</h3><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc75f53073be8992ce4f8cf58d4ebd0a\" tg-width=\"539\" tg-height=\"264\"><span>Zoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. Quote</span></p><p><blockquote><h3>Zoom Video通信公司。价格和每股收益惊喜</h3><p class=\"t-img-caption\"><span>Zoom Video通信公司价格-每股收益-惊喜|Zoom Video通信公司报价</span></p></blockquote></p><p>Zoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.</p><p><blockquote>Zoom的收益在过去四个季度都超过了Zacks的普遍预期，平均意外率为73.2%。</blockquote></p><p>Let’s see how things have shaped up for this announcement.</p><p><blockquote>让我们看看这个公告的进展如何。</blockquote></p><p><h3>Factors to Watch</h3>Zoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.</p><p><blockquote><h3>值得关注的因素</h3>尽管开展了疫苗接种活动，但Zoom第一财季的收入预计仍将受益于冠状病毒引发的在家工作和在线学习浪潮。</blockquote></p><p>Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.</p><p><blockquote>值得注意的是，该公司的免费增值商业模式帮助其快速赢得客户，然后可以将这些客户转化为付费客户。2021财年第四季度，过去12个月的美元净增长率超过156%。预计这一势头将在即将报告的季度持续下去。</blockquote></p><p>Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.</p><p><blockquote>此外，支持商务专业人士远程工作的Zoom For Home的可用性是一个关键的催化剂。</blockquote></p><p>Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of <b>Atlassian</b>, <b><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a></b> and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</p><p><blockquote>此外，这家Zacks排名第二（购买）的公司拥有强大的合作伙伴基础，其中包括<b>Atlassian</b>,<b><a href=\"https://laohu8.com/S/NOW\">服务现在</a></b>和Dropbox，预计将使该公司在第一财季赢得企业客户方面受益。你可以在这里看到今天咤克斯排名第一（强力买入）股票的完整列表。</blockquote></p><p>However, Zoom Video continues to face significant competition from the likes of <b>Cisco</b>, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.</p><p><blockquote>然而，Zoom Video继续面临来自以下公司的激烈竞争<b>思科</b>、微软和谷歌相遇。这可能会导致中小型企业客户的流失，从而可能会损害营收增长。</blockquote></p><p><h3>Key Q1 Highlights</h3>During the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.</p><p><blockquote><h3>第一季度主要亮点</h3>在即将报告的季度中，Zoom宣布了一项名为Zoom Apps Fund的1亿美元风险基金，旨在刺激Zoom的Zoom应用、集成、开发者平台和硬件生态系统的增长。</blockquote></p><p>Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.</p><p><blockquote>此外，在本季度，Zoom和一级方程式宣布，他们已在即将到来的2021年国际汽联一级方程式世界锦标赛赛季及以后建立了新的广泛的多年合作伙伴关系。</blockquote></p><p>Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.</p><p><blockquote>此外，在2月份，Zoom宣布推出Zoom Rooms，这将帮助组织安全地重新进入办公室，并维持“无处不在的员工”。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将报告第一季度收益：前景如何？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将报告第一季度收益：前景如何？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Zacks</strong><span class=\"h-time small\">2021-06-01 19:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</b> is set to report first-quarter fiscal 2022 results on Jun 1.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a>视频通信</b>定于6月1日公布2022财年第一季度业绩。</blockquote></p><p>For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.</p><p><blockquote>该公司预计本季度非GAAP每股收益在95美分至97美分之间。总收入预计在9亿美元至9.05亿美元之间。</blockquote></p><p>The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.</p><p><blockquote>过去30天，Zacks对收益的一致预期保持在每股97美分。该公司报告去年同期每股收益为20美分。</blockquote></p><p>The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.</p><p><blockquote>收入的共识为9.052亿美元，比去年同期报告的数字增长175.8%。</blockquote></p><p><h3>Zoom Video Communications, Inc. Price and EPS Surprise</h3><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc75f53073be8992ce4f8cf58d4ebd0a\" tg-width=\"539\" tg-height=\"264\"><span>Zoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. Quote</span></p><p><blockquote><h3>Zoom Video通信公司。价格和每股收益惊喜</h3><p class=\"t-img-caption\"><span>Zoom Video通信公司价格-每股收益-惊喜|Zoom Video通信公司报价</span></p></blockquote></p><p>Zoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.</p><p><blockquote>Zoom的收益在过去四个季度都超过了Zacks的普遍预期，平均意外率为73.2%。</blockquote></p><p>Let’s see how things have shaped up for this announcement.</p><p><blockquote>让我们看看这个公告的进展如何。</blockquote></p><p><h3>Factors to Watch</h3>Zoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.</p><p><blockquote><h3>值得关注的因素</h3>尽管开展了疫苗接种活动，但Zoom第一财季的收入预计仍将受益于冠状病毒引发的在家工作和在线学习浪潮。</blockquote></p><p>Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.</p><p><blockquote>值得注意的是，该公司的免费增值商业模式帮助其快速赢得客户，然后可以将这些客户转化为付费客户。2021财年第四季度，过去12个月的美元净增长率超过156%。预计这一势头将在即将报告的季度持续下去。</blockquote></p><p>Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.</p><p><blockquote>此外，支持商务专业人士远程工作的Zoom For Home的可用性是一个关键的催化剂。</blockquote></p><p>Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of <b>Atlassian</b>, <b><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a></b> and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</p><p><blockquote>此外，这家Zacks排名第二（购买）的公司拥有强大的合作伙伴基础，其中包括<b>Atlassian</b>,<b><a href=\"https://laohu8.com/S/NOW\">服务现在</a></b>和Dropbox，预计将使该公司在第一财季赢得企业客户方面受益。你可以在这里看到今天咤克斯排名第一（强力买入）股票的完整列表。</blockquote></p><p>However, Zoom Video continues to face significant competition from the likes of <b>Cisco</b>, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.</p><p><blockquote>然而，Zoom Video继续面临来自以下公司的激烈竞争<b>思科</b>、微软和谷歌相遇。这可能会导致中小型企业客户的流失，从而可能会损害营收增长。</blockquote></p><p><h3>Key Q1 Highlights</h3>During the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.</p><p><blockquote><h3>第一季度主要亮点</h3>在即将报告的季度中，Zoom宣布了一项名为Zoom Apps Fund的1亿美元风险基金，旨在刺激Zoom的Zoom应用、集成、开发者平台和硬件生态系统的增长。</blockquote></p><p>Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.</p><p><blockquote>此外，在本季度，Zoom和一级方程式宣布，他们已在即将到来的2021年国际汽联一级方程式世界锦标赛赛季及以后建立了新的广泛的多年合作伙伴关系。</blockquote></p><p>Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.</p><p><blockquote>此外，在2月份，Zoom宣布推出Zoom Rooms，这将帮助组织安全地重新进入办公室，并维持“无处不在的员工”。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568\">Zacks</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"source_url":"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138889344","content_text":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.Zoom Video Communications, Inc. Price and EPS SurpriseZoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. QuoteZoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.Let’s see how things have shaped up for this announcement.Factors to WatchZoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of Atlassian, ServiceNow and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.However, Zoom Video continues to face significant competition from the likes of Cisco, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.Key Q1 HighlightsDuring the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.","news_type":1,"symbols_score_info":{"ZM":0.9}},"isVote":1,"tweetType":1,"viewCount":2709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111320436,"gmtCreate":1622653635125,"gmtModify":1631889244285,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111320436","repostId":"2140448417","repostType":4,"isVote":1,"tweetType":1,"viewCount":2796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136463833,"gmtCreate":1622036288122,"gmtModify":1631892032982,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/136463833","repostId":"2138105101","repostType":4,"isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191070754,"gmtCreate":1620830434978,"gmtModify":1631885993771,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SBUX\">$Starbucks(SBUX)$</a>dhisndf","listText":"<a href=\"https://laohu8.com/S/SBUX\">$Starbucks(SBUX)$</a>dhisndf","text":"$Starbucks(SBUX)$dhisndf","images":[{"img":"https://static.tigerbbs.com/727543736fc358cc12dc1929f8d98814","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/191070754","isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":111963117,"gmtCreate":1622649396339,"gmtModify":1631889244292,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".&nbsp;","listText":".&nbsp;","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111963117","repostId":"1188552613","repostType":4,"repost":{"id":"1188552613","kind":"news","pubTimestamp":1622627641,"share":"https://www.laohu8.com/m/news/1188552613?lang=zh_CN&edition=full","pubTime":"2021-06-02 17:54","market":"us","language":"en","title":"AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC股价再次飙升。如何理解这一举动。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188552613","media":"Barrons","summary":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, th","content":"<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of&nbsp;GameStop&nbsp;and&nbsp;BlackBerry&nbsp;into speculative territory.</p><p><blockquote>AMC院线股价飙升很容易被视为迷因交易疯狂，社交媒体推动的投资者狂热将游戏驿站和黑莓等公司带入了投机领域。</blockquote></p><p> But it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.</p><p><blockquote>但传统投资者可能错过了电影院业务的根本性变化——而且这已经不是第一次了。</blockquote></p><p> Shares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office.&nbsp;Shares were up another 34%, to $42.92, in premarket trading Wednesday.</p><p><blockquote>AMC（股票代码：AMC）股价周二飙升23%，收于32.04美元，略低于5月底创下的36.72美元的历史高点。这使得这家连锁影院的市值约为160亿美元，是2018年票房破纪录的一年的15倍多。周三盘前交易中，该公司股价又上涨34%，至42.92美元。</blockquote></p><p> Even if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.</p><p><blockquote>不过，即使投资者错过了拐点，数学也不成立。原因可能是市值不是正确的衡量标准。也许是企业价值，本质上是市值和债务。AMC的企业价值约为260亿美元，而2018年底为62亿美元左右。</blockquote></p><p> AMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.</p><p><blockquote>AMC在疫情期间增加了债务，因为该国最大城市的影院连续几个月处于黑暗之中。这些数字很容易理解原因：2020年美国票房收入约为21亿美元，比2018年创纪录的119亿美元下降了81%。</blockquote></p><p> So, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.</p><p><blockquote>因此，投资者似乎对电影院经济感到恼火。但这不是第一次了。这个行业在世纪之交基本上破产了。例如，富豪影院于2001年宣布破产。</blockquote></p><p> Back then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.</p><p><blockquote>当时，该行业有足够的容量，因为一种新的剧院设计——体育场座位可以更好地观看屏幕。这种转变意味着连锁电影院必须翻新，否则就有可能失去所有顾客到视野更好的电影院。最终，太多的座位和不够的顾客意味着体育场座位投资的回报从未实现。</blockquote></p><p> The upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&amp;P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.</p><p><blockquote>结果是整合。随着操作员的减少，屏幕数量稳定下来。2002年至2007年间，Regal Cinemas因股票定价错误而成为现金产生机器。该股平均每年回报率为21%。同期，标普500和道琼斯工业平均指数的平均年回报率均低于9%。</blockquote></p><p> In those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.</p><p><blockquote>当年，富豪影院的企业价值约为50亿美元，约占美国票房总收入的50%。这与今天的AMC相去甚远。新的东西必须与众不同，AMC才值得。</blockquote></p><p> Maybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.</p><p><blockquote>也许电影院业务又要经历一段盘整期，可以迎来又一个回报的黄金时代。事实上，AMC周二的上涨是由筹集的新资本推动的，因此该公司可以继续进攻，收购已倒闭的连锁店。毕竟，垄断有利于股票回报。</blockquote></p><p> If AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.</p><p><blockquote>如果AMC能够增加市场份额，并且美国票房销售额能够在几年内恢复到2018年的水平，那么总销售额可能会达到90亿美元——60亿美元来自门票，30亿美元来自特许经营。2018年销售额达55亿美元。</blockquote></p><p> Then, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&amp;P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.</p><p><blockquote>然后，随着规模的扩大带来更好的毛利率，AMC每年可能能够产生6亿美元的自由现金流，这使得该股的自由现金流收益率约为4%。标普500的自由现金流收益率约为3%。这些数字可以发挥作用——如果它们被拉伸的话。</blockquote></p><p> There are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.</p><p><blockquote>不过，这种情况存在问题。有很多如果和可能——AMC过去从未产生过这样的现金流。达到6亿美元的自由现金流更多的是为了证明当前估值的合理性，而不是预测可能发生的情况。</blockquote></p><p> Also, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.</p><p><blockquote>此外，通过并购，AMC的市场份额可能会上升，但仍然存在竞争对手。富豪影院仍然存在，归电影世界控股公司所有。伦敦）。喜满客（CNK）也是如此。没有真正的垄断。</blockquote></p><p> AMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.</p><p><blockquote>AMC及其同行也必须应对流媒体问题。独家影院放映的窗口正在缩小。疫情加速了这一点。如果AMC变得太大，对电影制作人的要求太高，人才总是可以更快地转向流媒体，从而损害票房销售。</blockquote></p><p> There is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.</p><p><blockquote>还有同行股票的问题。他们并不认为这是剧院的一个勇敢的新世界。Cineworld股价较52周低点上涨484%，但仍较历史高点下跌72%。喜满客股价较52周低点上涨222%。它们比历史高点下跌了47%。</blockquote></p><p> AMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.</p><p><blockquote>AMC股价再次较52周低点上涨近1,600%，较5月份历史高点仅下跌13%。</blockquote></p><p> Wall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.</p><p><blockquote>华尔街也没有看到潜力。九名分析师关注该股。分析师平均目标价约为5美元。在疫情爆发之前，分析师的平均目标价为15美元。但当时股票较少。旧的目标企业价值约为70亿美元。很难从70亿美元增加到260亿美元来预测更好的利润率。</blockquote></p><p></p><p> Analysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.</p><p><blockquote>不过，分析师确实模拟了正自由现金流——2022年为1300万美元，2023年为9000万美元。这距离6亿美元还有很长的路要走。</blockquote></p><p> And that’s just another way of saying that AMC bulls are a long way from making the math work.</p><p><blockquote>这只是AMC多头距离实现数学计算还有很长的路要走的另一种说法。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC股价再次飙升。如何理解这一举动。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC股价再次飙升。如何理解这一举动。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-06-02 17:54</span>\n</p>\n</h4>\n</header>\n<article>\n<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of&nbsp;GameStop&nbsp;and&nbsp;BlackBerry&nbsp;into speculative territory.</p><p><blockquote>AMC院线股价飙升很容易被视为迷因交易疯狂，社交媒体推动的投资者狂热将游戏驿站和黑莓等公司带入了投机领域。</blockquote></p><p> But it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.</p><p><blockquote>但传统投资者可能错过了电影院业务的根本性变化——而且这已经不是第一次了。</blockquote></p><p> Shares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office.&nbsp;Shares were up another 34%, to $42.92, in premarket trading Wednesday.</p><p><blockquote>AMC（股票代码：AMC）股价周二飙升23%，收于32.04美元，略低于5月底创下的36.72美元的历史高点。这使得这家连锁影院的市值约为160亿美元，是2018年票房破纪录的一年的15倍多。周三盘前交易中，该公司股价又上涨34%，至42.92美元。</blockquote></p><p> Even if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.</p><p><blockquote>不过，即使投资者错过了拐点，数学也不成立。原因可能是市值不是正确的衡量标准。也许是企业价值，本质上是市值和债务。AMC的企业价值约为260亿美元，而2018年底为62亿美元左右。</blockquote></p><p> AMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.</p><p><blockquote>AMC在疫情期间增加了债务，因为该国最大城市的影院连续几个月处于黑暗之中。这些数字很容易理解原因：2020年美国票房收入约为21亿美元，比2018年创纪录的119亿美元下降了81%。</blockquote></p><p> So, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.</p><p><blockquote>因此，投资者似乎对电影院经济感到恼火。但这不是第一次了。这个行业在世纪之交基本上破产了。例如，富豪影院于2001年宣布破产。</blockquote></p><p> Back then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.</p><p><blockquote>当时，该行业有足够的容量，因为一种新的剧院设计——体育场座位可以更好地观看屏幕。这种转变意味着连锁电影院必须翻新，否则就有可能失去所有顾客到视野更好的电影院。最终，太多的座位和不够的顾客意味着体育场座位投资的回报从未实现。</blockquote></p><p> The upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&amp;P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.</p><p><blockquote>结果是整合。随着操作员的减少，屏幕数量稳定下来。2002年至2007年间，Regal Cinemas因股票定价错误而成为现金产生机器。该股平均每年回报率为21%。同期，标普500和道琼斯工业平均指数的平均年回报率均低于9%。</blockquote></p><p> In those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.</p><p><blockquote>当年，富豪影院的企业价值约为50亿美元，约占美国票房总收入的50%。这与今天的AMC相去甚远。新的东西必须与众不同，AMC才值得。</blockquote></p><p> Maybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.</p><p><blockquote>也许电影院业务又要经历一段盘整期，可以迎来又一个回报的黄金时代。事实上，AMC周二的上涨是由筹集的新资本推动的，因此该公司可以继续进攻，收购已倒闭的连锁店。毕竟，垄断有利于股票回报。</blockquote></p><p> If AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.</p><p><blockquote>如果AMC能够增加市场份额，并且美国票房销售额能够在几年内恢复到2018年的水平，那么总销售额可能会达到90亿美元——60亿美元来自门票，30亿美元来自特许经营。2018年销售额达55亿美元。</blockquote></p><p> Then, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&amp;P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.</p><p><blockquote>然后，随着规模的扩大带来更好的毛利率，AMC每年可能能够产生6亿美元的自由现金流，这使得该股的自由现金流收益率约为4%。标普500的自由现金流收益率约为3%。这些数字可以发挥作用——如果它们被拉伸的话。</blockquote></p><p> There are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.</p><p><blockquote>不过，这种情况存在问题。有很多如果和可能——AMC过去从未产生过这样的现金流。达到6亿美元的自由现金流更多的是为了证明当前估值的合理性，而不是预测可能发生的情况。</blockquote></p><p> Also, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.</p><p><blockquote>此外，通过并购，AMC的市场份额可能会上升，但仍然存在竞争对手。富豪影院仍然存在，归电影世界控股公司所有。伦敦）。喜满客（CNK）也是如此。没有真正的垄断。</blockquote></p><p> AMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.</p><p><blockquote>AMC及其同行也必须应对流媒体问题。独家影院放映的窗口正在缩小。疫情加速了这一点。如果AMC变得太大，对电影制作人的要求太高，人才总是可以更快地转向流媒体，从而损害票房销售。</blockquote></p><p> There is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.</p><p><blockquote>还有同行股票的问题。他们并不认为这是剧院的一个勇敢的新世界。Cineworld股价较52周低点上涨484%，但仍较历史高点下跌72%。喜满客股价较52周低点上涨222%。它们比历史高点下跌了47%。</blockquote></p><p> AMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.</p><p><blockquote>AMC股价再次较52周低点上涨近1,600%，较5月份历史高点仅下跌13%。</blockquote></p><p> Wall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.</p><p><blockquote>华尔街也没有看到潜力。九名分析师关注该股。分析师平均目标价约为5美元。在疫情爆发之前，分析师的平均目标价为15美元。但当时股票较少。旧的目标企业价值约为70亿美元。很难从70亿美元增加到260亿美元来预测更好的利润率。</blockquote></p><p></p><p> Analysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.</p><p><blockquote>不过，分析师确实模拟了正自由现金流——2022年为1300万美元，2023年为9000万美元。这距离6亿美元还有很长的路要走。</blockquote></p><p> And that’s just another way of saying that AMC bulls are a long way from making the math work.</p><p><blockquote>这只是AMC多头距离实现数学计算还有很长的路要走的另一种说法。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188552613","content_text":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into speculative territory.\nBut it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.\nShares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office. Shares were up another 34%, to $42.92, in premarket trading Wednesday.\nEven if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.\nAMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.\nSo, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.\nBack then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.\nThe upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.\nIn those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.\nMaybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.\nIf AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.\nThen, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.\nThere are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.\nAlso, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.\nAMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.\nThere is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.\nAMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.\nWall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.\nAnalysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.\nAnd that’s just another way of saying that AMC bulls are a long way from making the math work.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":2624,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135084783,"gmtCreate":1622122701142,"gmtModify":1631889244340,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".guu ya n","listText":".guu ya n","text":".guu ya n","images":[{"img":"https://static.tigerbbs.com/f718b1732852edbe5f41671c8998e94e","width":"1125","height":"3282"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/135084783","isVote":1,"tweetType":1,"viewCount":2794,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":135086323,"gmtCreate":1622122619562,"gmtModify":1631892032979,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/135086323","repostId":"2138912120","repostType":4,"isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":194835491,"gmtCreate":1621352496813,"gmtModify":1631892032990,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/194835491","repostId":"2136995492","repostType":4,"isVote":1,"tweetType":1,"viewCount":853,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191054560,"gmtCreate":1620829586050,"gmtModify":1631892033008,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579418112520180","authorIdStr":"3579418112520180"},"themes":[],"htmlText":"Uppppzz&nbsp;","listText":"Uppppzz&nbsp;","text":"Uppppzz","images":[{"img":"https://static.tigerbbs.com/49fdd8247005beda8b462ba7c63653b9","width":"1125","height":"2874"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/191054560","isVote":1,"tweetType":1,"viewCount":391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}